NHS South Yorkshire Integrated Care Board

NHS South Yorkshire Integrated Medicines Optimisation Committee (IMOC)

SY Prescribed Product Classification List

Oct-26

*****This list is in development and is being led by the SY IMOC, currently it does not include medicines where the 4 places (Barnsley, Doncaster and Bassetlaw, Rotherham and Sheffield) have previously agreed a place based traffic light status. Harmonisation of placed based Traffic Light Drug Lists (TLDL) is underway with the long-term vision to have one prescribed product list for South Yorkshire. Work is underway to align existing SY traffic light classifications with the new categorisation framework within the Single National Formulary. During the transition period, both classification systems will operate in parallel.**

Due to the extensive number of green drugs, currently not all will be listed within the SY prescribed product list. During the process of merging the 4 place TLDLs

across South Yorkshire,green drugs will be added to the SY prescribed product list as they are considered.It should not be assumed that those listed are first line medicines,

place guidelines/ formularies should be followed . If clarification is needed for a medicine not listed in the SY Prescribed Product List,clinicians can seek advice from the SY ICB Medicines Optimisation Team.

****Formulary Status: From October 2026, formulary status decisions for medicines will be considered through IMOC. During the transition period, Place and South Yorkshire formularies will operate in parallel to support alignment and continuity of decision-making. ****

	Do not prescribe(previously known as Grey Traffic light Status)		**Specialist only**(previously known as Red traffic Light Status)		**All settings** (previously known as Green status)
	Self care				
	Shared Care(previously know as Amber Traffic Light Status)		**Specialist advice** (previously known as Amber G Traffic Light Status)		**Specialist initiation** (previously known as Amber G Traffic Light Status)

Refer to the user guide for Single National Formulary (SNF) :

Remember : Control + F to search this list

SY Place based Formularies :	
Barnsley Place Formulary	Rotherham Place Formulary
Doncaster Place Formulary	Sheffield Place Traffic Light Drug

Category (Traffic Light Status)	Preferencing recommendation (First line, Second line, Other, Non-formulary, Hospital only)	Drug/Product	Brand name	Rationale / criteria	Notes	Date Considered	Review date	Relevant Links
Grey		Aceclofenac		3	Non-steroidal anti-inflammatory	Jun-23		
Grey		Adagrasib		6	Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)	Aug-25		NICE TA1076
Grey		Adrenaline (nasal spray formulation) (Dual Traffic Light status)	EURneffy®	7	Emergency treatment of severe allergic reactions (anaphylaxis)	Dec-25		
Grey		Afamelanotide		1	Erythropoietic protoporphyria	Sep-23		
Grey		Agomelatine		3	Major Depression	Jun-23		NICE TA821

Grey		Alimemazine (dual traffic light classification)		4	All licensed indications- urticaria and pruritus(already traffic lighted Amber if initiated for sleep disorders in children by tertiary sleep service in SCH (unlicensed indication)	Feb-25		
Grey		Aliskiren		1	Hypertension	Jun-23		Link to NHSE LLP1
Grey		Almotriptan		4	Refer to Place based formularies / guidelines for alternative listing	Jun-24	Jun-25	Link to NHSE LLP1
Grey		Amantadine (Multiple traffic light classification)		2	Influenza	Jun-23		
Grey		Amifampridine (3,4 diaminopyridine phosphate)		1	Lambert-Eaton Myasthenic Syndrome (LEMS) in adults	Jun-23		
Grey		Anakinra (dual traffic light classification)		2	Rheumatoid arthritis in adults	Jun-23		NICE NG100 Also see reference to Red traffic light status
Grey		Angiotensin II		2	Treatment of refractory hypotension in adults with septic or other distributive shock	Apr-24		
Grey		Antimalarials (dual traffic light combination)		2	Prophylaxis treatment of malaria	Apr-24		Drugs for malaria prophylaxis are not prescribable on the NHS. Chloroquine & atovaquone 250 mg / proguanil 100mg is available to buy over-the-counter. Mefloquine and doxycycline are only available on private prescription.

Grey		Aprocitentan		6	Resistant hypertension	Apr-25		
Grey		Armour thyroid (desiccated thyroid extract)		1	Hypothyroidism	Jun-23		Link to SPS advice
Grey		Atorvastatin 30mg and 60mg tablets		4	For cost-effective prescribing it is recommended that for patients requiring a 30mg or 60mg dose to use 10mg or 20mg tablets	Jun-24	Jun-25	
Grey		Avanafil		4	Erectile dysfunction	Feb-24		
Grey		Azathioprine 75mg & 100mg strengths (dual Traffic Light Status)		3		Apr-24		
Grey		Azilsartan		4	Hypertension	Feb-24		
Grey		Baloxavir marboxil		2	Uncomplicated influenza and post exposure prophylaxis of influenza in patients aged 12 years and above	Jun-23		
Grey		Baloxavir marboxil		7	Treating and preventing influenza in children 1 to 11 years (terminated appraisal)	Mar-26		NICE TA1135
Grey		Bemiparin		6	All licensed indications	Jun-23		
Do not prescribe	Not Preferred	Brensocatib			Non-cystic fibrosis bronchiectasis (NCFB).	Sep-26		Terminated evaluation

Grey		Calcifediol	Domnisol®	7	Treatment of vitamin D deficiency in adults, prevention of vitamin D deficiency in adults with identified risks, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency	Dec-23		
Grey		Cangrelor tetrasodium		7	Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy	Jan-26		NICE TA1102
Grey		Casirivimab plus imdevimab		1	Covid-19 Treatment	Jun-23		NICE TA878
Grey		Cedazuridine + decitabine		2	Acute myeloid leukaemia	Mar-24		
Grey		Cerliponase alfa		7	Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2	Mar-26		HST34
Grey		Chikungunya vaccine		6	Active immunisation for the prevention of disease caused by chikungunya virus	Aug-25		
Grey		Chondroitin (all salts, all strengths)		1,2	All Indications	Jul-23		In NHSE guidance
Grey		Ciclesonide	Alvesco®	4	Refer to Place based formularies / guidelines for alternative listing	Sep-23		

Grey		Cilostazol		2	Intermittent claudication in patients without rest pain and no peripheral tissue necrosis	Jul-23		NICE TA223
Grey		Ciltacabtagene autoleucel		6	Treatment of adults with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide	Mar-25		
Grey		Ciprofibrate		4	Refer to Place based formularies / guidelines for alternative listing	Jul-24		
Grey		Clascoterone		6	Topical treatment of acne vulgaris in patients aged ≥12 years	May-25		
Grey		Clascoterone		6	For treating acne vulgaris in people 12 years and over (terminated appraisal)	Nov-25		NICE TA1105
Grey		Clobetasol propionate/neomycin sulphate/nystatin 0.5mg/5mg/100,000 IU/g Cream/ointment		4	Refer to Place based formularies / guidelines for alternative listing	Jul-23		
Grey		Cobimetinib		2	Unresectable or metastatic melanoma in adults	Jul-23		NICE TA414

Grey		Co-diovan		4	Hypertension	Sep-23		For cost-effective prescribing it is recommended that valsartan plus bendroflumethiazide should be prescribed separately
Grey		Concizumab		6	Treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)	May-26		NICE TA1124
Grey		Co-Proxamol		1	All licensed indications	Jun-23		NHSE Guidance
Grey		Cyanocobalamin 50 microgram tablets (dual traffic light combination)		1	Dietary Supplement	May-23		NHSE items that should not routinely prescribed Also see reference to Green traffic light status
Grey		Darifenacin		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey		Darvadstrocel		2	Fistulas (perianal) in adult patients with non-active/mildly active luminal Crohn's disease.	Sep-23		
Grey		Decitabine (Including combinations)		7	Myeloid Leukaemia	Nov-24		Decitabine NICE Information
Grey		Deflazacort		4	Steriod	Feb-24	Feb-25	
Grey		Dekas plus liquid (dual traffic light classification)			Non- Cystic fibrosis patients Also see Green for children under 3 with cystic fibrosis	Oct-23		
Grey		Dengue vaccine	Qdenga®	1	Prevention of dengue disease in individuals aged ≥4 years	Oct-23		

Grey		Depemokimab		7	Treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)	Feb-26		NICE TA1123
Grey		Dexketoprofen		5	Nonsteroidal anti-inflammatory drug (NSAID)	Feb-24		
Grey		Dicycloverine Hydrochloride tablets		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		Medicines Optimisation Information
Grey		Diphtheria + tetanus + pertussis vaccine		6	Active immunisation against tetanus, diphtheria and pertussis in persons aged ≥4 years as a booster following primary immunisation. Also for passive protection against pertussis in early infancy following maternal immunisation during pregnancy	May-24		
Grey		Donanemab		6	Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adults that are apolipoprotein E ε4 heterozygotes or non-carriers	Jan-25		
Grey		Dosulepin		1	Depressive illness, particularly where sedation is required	Jun-23		Link to NHSE LLP1
Grey		Doxazosin MR preparations		1	Hypertension	Jun-23		Link to NHSE LLP1

Grey		Doxepin		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey		Doxepin cream		3	Pruritus in eczema	Jul-23		
Grey		Dutasteride 500mcg plus tamsulosin 400microgram		4	For cost-effective prescribing it is recommended that Dutasteride and Tamsulosin are prescribed separately	Sep-23		
Grey		Efgartigimod for treating antibody-positive generalised myasthenia gravis		2	Efgartigimod for treating antibody-positive generalised myasthenia gravis	Jul-25		NICE TA 1069
Grey		Elacestrant		6	Use as monotherapy for the treatment of postmenopausal women and men with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor	Nov-24		
Grey		Elinzanetant	Lynkuet®	6	Indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause	Jul-26		NICE TAs in development
Grey		Elotuzumab		7	For previously treated multiple myeloma	May-25		Elotuzumab NICE information

Grey		Entrectinib		7	for treating NTRK fusion-positive solid tumours in people 12 years and over.	Feb-26		NICE TA1118
Grey		Epcoritamab		5	Monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy	Feb-24		
Grey		Erdosteine		3	Symptomatic treatment of acute exacerbations of chronic bronchitis	Jul-25		
Grey		Eroxon Stimgel		7	Treatment of erectile dysfunction in adult men [medical device – gel formulation of volatile solvent components]	Jun-23		
Grey		Esketamine		2	Major depressive disorder in adults at imminent risk of suicide	Jul-23		NICE TA899
Grey		Esketamine Nasal spray		2	Depression	Sep-23		
Grey		Eszopiclone		7	Insomnia	Apr-25		
Grey		Eyelid hygiene preparations		3	Examples : wipes,lotions	Sep-23		
Grey		Fampridine		2	Multiple sclerosis	Sep-23		NICE NG220
Grey		Fentanyl (Immediate release)		1	For patients not undergoing palliative care treatment as per NHSE guidelines	Dec-23		NHS E Guideline

Grey		Fluoxetine 10mg tablets (refer to the green entry for other strengths/formulations)		4	Cross reference to green traffic light entry for other strengths/formulations	Mar-26		The capsule formulation has a significantly lower acquisition cost
Grey		Flurbiprofen tablets		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey		Fluvastatin 80mg		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey		Fosdenopterin		7	Treating molybdenum cofactor deficiency type A (terminated appraisal)	Aug-25		NICE TA1078
Grey		Gamolenic acid (Evening Primrose Oil)		3		Sep-23		
Grey		Ganaxolone		2	Treating seizures caused by CDKL5 deficiency disorder in people 2 years and over	Mar-25		
Grey		Gefapixant		7	Refractory or unexplained chronic cough	Jun-24		
Grey		Givinostat		6	Treatment of Duchenne muscular dystrophy in patients aged 6 years and older	Apr-26		NICE TA in development
Grey		Glasdegib		1	Terminated NICE TA	Sep-23		NICE TA646
Grey		Glucosamine and chondroitin		1		Sep-23		NHSE guidance

Grey		Gluten Free products			Coeliac Disease, gluten sensitive enteropathies, dermatitis herpetiformis or other gluten intolerances in line with SYICB position statement	Jan-26		SY Gluten Free information
Grey		Gonadotrophin releasing hormone (GnRH) analogues drugs- medicines that consist of, or contain, buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin.		2	Used to suppress puberty as part of treating gender incongruence or gender dysphoria in children and young people who are under 18 years of age	Jun-24		NHSE Information
Grey		Herbal treatments		1	Not Recommended	Oct-23		NHSE document
Grey		Homeopathic treatments		1	Not Recommended	Oct-23		NHSE document
Grey		Human alpha1-proteinase inhibitor		7	Treating emphysema	May-24		
Grey		Hyaluronic acid Intra-articular injections		2	Do not offer intra-articular hyaluronan injections to manage osteoarthritis	Oct-23		NICE NG226
Grey		Idecabtagene vicleucel		6	Treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)	Aug-25		NICE TA 1084
Grey		Imlunestrant		7	Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)	Jul-26		NICE TA 1168

Grey		Imlunestrant	Inluriyo®	6	Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see section 4.2). In pre- or perimenopausal women, or men, Inluriyo should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Jul-26		NICE TA in development

Grey		Inavolisib		6	Use in combination with palbociclib and fulvestrant for the treatment of adults with PIK3CA-mutated, oestrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.	Apr-26		NICE TA in development
Grey		Inebilizumab		7	Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)	Jun-26		NICE TA 1151
Grey		Inositol nicotinate		2	Intermittent claudication in people with peripheral arterial disease	Oct-23		
Grey		Insulin needles >£5 per 100 needles		4		Sep-23		Refer to Place based formularies/ guidelines supported by NHSE document
Grey		Iptacopan		1,6	Treating complement 3 glomerulopathy	Dec-25		NICE TA1107
Grey		IQoro		3	Neuromuscular training device	Feb-23		

Grey		Ketoprofen (topical)		3	Areas of skin treated with Ketoprofen 2.5 % Gel should not be exposed to direct sunlight, or solarium ultraviolet light, either during treatment or for two weeks following treatment discontinuation, in order to avoid phototoxicity reactions and photoallergy	Oct-23		
Grey		Lazertinib		6	Advanced non-small cell lung cancer	Jun-25		On publication of NICE TA
Grey		Lecanemab		6	Alzheimer's disease	Feb-25		
Grey		Leniolisib phosphate		6	Indicated for the treatment of activated phosphoinositide 3- kinase delta (P13Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older.	Mar-25		
Grey		Levodopa inhalation powder	Inbrija®	7	Intermittent treatment of episodic motor fluctuations (OFF episodes) in adults with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor	Nov-25		
Grey		Loxapine		2	Mild-to-moderate agitation in patients with schizophrenia or bipolar disorder	Oct-23		

Grey		Lutein and antioxidants (All dietary antioxidants and supplements to prevent AMD)		1	Age related macular degeneration (AMD)	Oct-23		NHSE document
Do not prescribe		Lutetium-177 vipivotide tetraxetan			for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)	Sep-26		NICE TA 1179
Grey		Melphalan flufenamide		7	Relapsed or refractory multiple myeloma	Jun-24		
Grey		Memantine orodispersible tablets (see amber G entry for other formulations of memantine)		4	Memantine tablets are 1st line. If oral solution is required for cost-effective prescribing it is recommended that oral solution is prescribed where clinically appropriate. See Place guidance for further prescribing information.	Nov-23	Nov-24	
Grey		Methocarbamol		1	Short-term symptomatic relief of muscle spasm	Nov-23		
Grey		Methylnaltrexone bromide injection		2	Execption prescribe on advice of the specialist Palliative Care team	Nov-23		
Grey		Minocycline		1	Acne Vulgaris and Acne Rosacea	Nov-23		NHSE guidelines
Grey		Mosunetuzumab		2	Follicular lymphoma	Nov-23		NICE Information
Grey		Naltrexone/bupropion prolonged-release tablets		2	Weight Management	Jul-23		NICE TA494

Grey		Necitumumab		2	Lung cancer	Nov-23		Necitumumab NICE information
Do not prescribe		Netarsudil			Open-angle glaucoma or ocular hypertension (terminated evaluation)	Sep-26		NICE TA1180
Grey		Nintedanib		6	Treating fibrosing interstitial lung disease in people 6 to 17 years	Dec-25		Nintedanib NICE Informormation
Grey		Niraparib + abiraterone		6	Use with prednisone or prednisolone for the treatment of adults with metastatic castration-resistant prostate cancer and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated	Apr-26		NICE TA in development
Grey		Nogapendekin alfa inbakicept		7	Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)	Jul-26		NICE TA 1163
Grey		Olipudase alfa		7	Treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B	May-25		NICE hst32
Grey		Olmesartan and amlodipine		4	For cost-effective prescribing it is recommended that olmesartan and amlodipine prescribed separately	Nov-23		

Grey		Omaveloxolone		7	Treating Friedreich's ataxia in people 16 years and over	Dec-25		NICE TA1061
Grey		Omega-3 fatty acids (Eicosapentaenoic acid /Docosahexaenoic acid)		1	For the primary and secondary prevention of cardiovascular events	Sep-23		NHSE guidance
Do not prescribe		Orforglipron (weight management)			As an adjunct to diet and exercise for weight management in adults with a BMI of: ≥30kg/m2 (obesity); or ≥27kg/m2 to <30kg/m2 (overweight) with at least one weight-related comorbidity.	Oct-26		NICE TAs for managing overweight and obesity in development.
Grey		Osilodrostat		1,7	Endogenous Cushing's syndrome	Nov-23		
Grey		Oxerutins		3	Oedema associated with chronic venous insufficiency	Nov-23		
Grey		Oxybutynin hydrochloride	Vesoxx	7	Managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)	Jun-26		NICE TA 1154
Grey		Padeliporfin		2	For untreated, unilateral, low-risk prostate cancer in adults	Dec-23		
Grey		Palopegteriparatide		6	Indicated for the treatment of adults with chronic hypoparathyroidism-	Oct-24		NICE TA in development
Grey		Paracetamol and tramadol combination		1	Analgesic	Dec-23		NHS E Guideline

Grey		Pegaptanib		2	Neovascular age related macular degeneration	Dec-23		
Grey		Pegylated liposomal irinotecan		7	Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer	May-25		NICE TA1052
Grey		Pentoxifylline		2	Intermittent claudication in people with peripheral arterial disease	Jul-23		NICE TA223
Grey		Perindopril arginine		1	Angiotensin converting enzyme (ACE) inhibitors	Dec-23		NHS E Guideline
Grey		Phenylephrine OTC preparations (oral/nasal) (dual classification)		1	For OTC preparations. See also see red list	Oct-25		
Grey		Pioglitazone and Metformin combination tablets		4	For cost-effective prescribing it is recommended that Pioglitazone and Metformin are prescribed separately	Dec-23	Dec-24	
Grey		Piroxicam (oral)		3	Nonsteroidal anti-inflammatory drug (NSAID)	Dec-23		
Grey		Pitolisant (dual classification)		2	Excessive daytime sleepiness caused by obstructive sleep apnea. See also Red for other indications	Dec-25		
Grey		Ranitidine		3	H2-receptor antagonists	Dec-23	Dec-24	
Grey		Recombinant Parathyroid hormone		1,6	All licensed indications	Oct-25		Parathyroid hormone NICE information

Grey		Rehydration solutions/sachets (dual traffic light status)		1	Self care-acute Diarrhoea (adults)	Feb-24		SY Selfcare Guide
Do not prescribe		Remibrutinib			For treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines	Oct-26		NICE TA in development
Grey		Resperate® Device		1		Dec-23		
Grey		Riboflavin		2,3	Migraine	Feb-24		NICE CG150 – can be purchased OTC
Do not prescribe		Rilzabrutinib			for treating persistent or chronic immune thrombocytopenia (terminated evaluation)	Oct-26		Rilzabrutinib for treating persistent or chronic immune thrombocytopenia
Grey		Rizatriptan lyophilisate	Maxalt®	4	Migraine	Feb-24	Feb-25	
Grey		Rosuvastatin Capsules		4	For cost effective option prescribe tablets, exception being opening capsules for swallowing difficulties & mixed with soft food for oral administration or administered via nasogastric tube.	Jul-24	Jul-25	
Grey		Rubefacients		1	Self- care - as per NHSE Guidelines	Dec-23		NHS E Guideline
Grey		Rupatadine		4	Refer to Place based formularies / guidelines for alternative	Dec-23	Dec-24	
Grey		Satralizumab		7	Preventing relapses in neuromyelitis optica spectrum disorders	May-24		Sarilumab NICE Information

Grey		Satralizumab		2	Use as a monotherapy or in combination with immunosuppressive therapy for the treatment of neuromyelitis optica spectrum disorders in adults and adolescents aged ≥12 years who are anti-aquaporin-4 IgG seropositive	Apr-24		
Grey		Sebelipase alfa (dual traffic light combination)		7	Lysosomal acid lipase (LAL) deficiency - long term enzyme replacement therapy (ERT) cross reference to Red TLS	Feb-24		
Grey		Self-care medicines - All Conditions for which over the counter items should not routinely be prescribed in primary care		5	Various Over the Counter medicines That are considered to be self-limiting i.e short term symptoms	Jun-23		
Do not prescribe	Not Preferred	Semaglutide tablets (weight management indication)	Wegovy®		Weight management	Sep-26		
Grey		Sildenafil brand: Viagra® (For Erectile Dysfunction) (multiple traffic light classifications)	Viagra®	4	Erectile Dysfunction. See also sildenafil entry in green and red sections. Follow Place formularies / guidelines for further information	Apr-25		

Grey		Silk Garments		1	In line with NHSE guidance Items not to be routinely prescribed in primary care	Dec-23		NHS E Guideline
Grey		Simple eye ointment		4	Refer to Place based formularies / guidelines for alternative	Dec-23		
Grey		Sirolimus gel		6	for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over	Jun-24		
Grey		Sodium Phenylbutyrate (Dual Classification)		6	For treating amyotrophic lateral sclerosis, see red traffic light list for other indications	Nov-25		Sodium Phenylbutyrate NICE information
Grey		Sulindac		3,4	Gout	Dec-23	Dec-24	
Grey		Sulthiame		6	Rolandic epilepsy	Apr-25		
Grey		Sumatriptan + naproxen sodium combination		4,7	Acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient	Jul-25		
Grey		Sumatriptan dispersible tablets	Imigran® Radis	4	Migraine	Feb-24	Feb-25	
Grey		Sun protection		Self care -1	Self care - Exception as per Advisory Committee on Borderline Substances (ACBS) approved indications.	Dec-23		
Grey		Tabelecleucel		2	Treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus	Nov-23		NICE TA923
Grey		Tadalafil 2.5mg only		4		Jul-24		

Grey		Tadalafil brand: Cialis® (For Erectile Dysfunction) (multiple traffic light classifications)	Cialis®	4	Erectile Dysfunction . See also tadalafil entries in green section and red sections. Follow Place formularies / guidelines for further information	Apr-25		
Grey		Tafamidis (dual traffic light combination)		2	Wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults Also see reference to Red traffic light status	Dec-23		
Grey		Tamsulosin plus solifenacin combination tablets		4	For cost-effective prescribing it is recommended that Tamsulosin and Solifenacin are prescribed separately	Dec-23	Dec-24	
Grey		Tamsulosin MR tablets		4	For cost-effective prescribing it is recommended that Tamsulosin MR capsules are prescribed	Dec-23	Dec-24	
Grey		Tarlatamab		6	Small cell lung cancer	Apr-25		
Grey		Telmisartan & Hydrochlorothiazide	Micardis Plus®	4	Refer to Place based formularies / guidelines for alternative listing	Nov-23		
Grey		Temsirolimus		2	All licensed indications	Feb-24		Temsirolimus NICE Information
Grey		Teprotumumab	Tepezza®	6	Use in adults for the treatment of moderate to severe thyroid eye disease	Dec-25		

Grey		Tiaprofenic acid		3	Pain and inflammation in rheumatic disease and other musculoskeletal disorders	Feb-24		Important safety information For tiaprofenic acid CSM advice
Grey		Tirzepatide weight management - any use outside of NICE TA1026 criteria [Multiple traffic light classifications]			Any patients that fall outside of NICE TA1026 criteria.	Nov-25		NICE TA1026
Grey		Tislelizumab		7	Terminated appraisals	Jul-25		NICE TA 1068 & TA 1072- terminated appraisals
Grey		Tixagevimab plus cilgavimab		2	Preventing COVID-19	Jul-23		NICE TA900
Grey		Tofersen	Qalsody®	6	Treatment of adults with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene	Dec-25		

Grey		Toripalimab	Loqtorzi®	6	In combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. In combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.	Jul-26		NICE TA in development
Grey		Trastuzumab deruxtecan		6	Treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments	Dec-25		
Grey		Travel Vaccines		1	Except for: cholera, diphtheria/tetanus/polio,hepatitis A, typhoid	Oct-23		NHSE Guidance
Grey		Trimipramine		1	Antidepressant	Jul-23		NHS E Guidance
Grey		Vinflunine		2	Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract	Feb-24		
Grey		Vitamin supplements and tonics		1	In line with SY Selfcare Guide	Feb-24		SY Selfcare Guide

Grey		Zilucoplan		6	Use as an add-on to standard therapy for the treatment of generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive	May-24		
Grey		Zuranolone	Zurzuvae®	6	Treatment of moderate or severe postnatal depression in adults following childbirth	Dec-25		
Red		Rezafungin		1,6	Treatment of adults with invasive candidiasis	May-24		
Red		Abacavir(including combinations)		1,6	HIV infection	Feb-24		
Red		Abaloparatide		1,6	Treating osteoporosis after menopause	Oct-24		
Red		Abatacept		1,6	In line with positive NICE TA recommendations	Feb-24		Abatacept NICE information
Red		Abciximab		1,6	Monoclonal antibody	Feb-24		
Red		Abemaciclib		1,6	In line with positive NICE TA recommendations	Feb-24		Abemaciclib NICE Information
Red		Abiraterone		1,6	In line with positive NICE TA recommendations	Feb-24		Abiraterone NICE Information
Red		Abrocitinib		1,6	Atopic dermatitis	Feb-24		
Specialist only		Acalabrutinib (including in combination)			In line with positive NICE TA recommendations	Sep-26		Acalabrutinib NICE Information
Red		Acetylcysteine ampoules		1	Emergency Treatment of Poisoning (paracetamol)	Feb-24		
Red		Aciclovir IV		1,6		Apr-24		
Red		Acitretin		1	Psoriasis	Feb-24		
Red		Acoramidis		1,6	Treating transthyretin amyloidosis with cardiomyopathy	Feb-26		NICE TA 1121

Red		Activated Charcoal		1,6	Emergency Treatment of Poisoning ('many oral poisons')	Apr-24		
Red		Activated Protein C	Ceprotin ®	1,6	Congenital protein C deficiency	Apr-24		
Red		Adalimumab		1,2,6	In line with positive NICE TA recommendations	Jun-23		Adalimumab NICE information
Red		Adefovir		1	Chronic hepatitis B	Feb-24		
Red		Adenosine	Adenocor®	1,6	Supraventricular arrhythmias	Apr-24		
Red		Afatinib		1,6	Non-small cell lung cancer	Feb-24		
Specialist only		Aficamten	Myqorzo		For treating symptomatic obstructive hypertrophic cardiomyopathy	Sep-26		NICE TA1181
Red		Aflibercept		1,2	In line with positive NICE TA recommendations	Jun-23		Afibercept NICE information
Red		Agalsidase alfa & beta		1,6	Fabry's disease	Apr-24		
Red		Albendazole		1,6		Apr-24		
Red		Albutrepenonacog alfa		1	Treatment and prophylaxis of bleeding in patients with haemophilia	Feb-24		
Red		Aldesleukin		1,6	In line with positive NICE TA recommendations	Apr-24		
Red		Alectinib		1,6	for adjuvant treatment of ALK-positive non-small-cell lung cancer	Dec-24		Alectinib NICE Information
Red		Alemtuzumab		1,6	In line with positive NICE TA recommendations	Jul-24		Alemtuzumab NICE information
Red		Alirocumab		1,6	Primary hypercholesterolaemia	Feb-24		
Red		Alitretinoin		1	Eczema - refractory chronic hand (severe)	Feb-24		
Red		All human coagulation factor IX		1	All licensed indications	Oct-25		

Red		All Intravenous nutrition		1,6		Apr-24		
Red		Alpelisib	Piqray®	1,6	Indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy	Apr-24		
Red		Alteplase		1,6		Apr-24		
Red		Ambrisentan		1	Pulmonary arterial hypertension	Feb-24		
Red		Amikacin		1,6	In line with positive NICE TA recommendations	Apr-24		
Red		Aminolevulinic acid products		1,5	Actinic keratosis on face, scalp (mild to moderate) and other body regions Field cancerisation. Basal cell carcinoma (superficial and/or nodular)	Feb-24		
Red		Aminophylline IV		1,6		Apr-24		
Red		Amivantamab (including in combination)		1,6	In line with positive NICE TA recommendations	Apr-24		Amivantamab NICE Information
Red		Amphotericin		1,6	Antifungal	Apr-24		
Red		Anagrelide		1,6	Polycythaemia vera, Thrombocytosis,	Apr-24		

Red		Anakinra (dual traffic light classification)		1,6	Still's disease & Gout Also see reference to Grey traffic light status	Feb-24		
Red		Andexanet alpha		1,6	In line with positive NICE TA recommendations	Feb-25		Andexanet+alfa NICE Information
Red		Anhydrous sodium thiosulfate		1,6	In line with positive NICE TA recommendations	Feb-25		Anhydrous+sodium+thiosulfate NICE Information
Red		Anidulafungin		1,6	Invasive candidiasis	Apr-24		
Red		Anti-D (Rh0) Immunoglobulin		1,6		Apr-24		
Red		Antihemophilic factor/Von Willebrand factor complex		1,6	Congenital Von Willebrand Disease	Apr-24		
Red		Anti-lymphocyte immunoglobulin (horse) (Atgam®)		1,6	Treatment of acquired moderate to severe aplastic anaemia	Apr-24		
Red		Antimalarials (dual traffic light classification)		1,6	For treatment of malaria	Apr-24		
Red		Antithrombin		1,6	VTE - Prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency	May-24		
Red		Anti-thymocyte immunoglobulin (Rabbit)		1,6	Immunosuppression in solid organ transplantation	Oct-25		
Red		Apalutamide		1,6	Prostate Cancer (non-metastatic castration-resistant)Metastatic Hormone Sensitive Prostate Cancer	May-24		

Specialist only		Apixaban (multiply categorisation)			Prevention of VTE after hip or knee replacement see also all settings category & Specialist Initation	Sep-26		
Red		Apraclonidine		1,6	Glaucoma (short-term adjunctive therapy of chronic glaucoma)	May-24		
Red		Apremilast		1,6	In line with positive NICE TA recommendations	Feb-24		Apremilast NICE information
Red		Aprepitant		1,6	Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.	May-24		
Red		Arachis hypogaea		1,6	Peanut Allergy	May-24		
Red		Argatroban		1,6	Anticoagulation of patients with heparin-induced thrombocytopenia type II requiring parenteral antithrombotic therapy	May-24		
Red		Argipressin		1,6	Indicated in adults for the treatment of diabetes insipidus, when this is not of nephrogenic origin, and for control of bleeding from oesophageal varices.	May-24		
Specialist only	Preferred -Hospital only- refer to local guidance where available	Aripiprazole (immediate release) injection			Schizophrenia, rapid control of agitation and disturbed behaviours in patients, when oral therapy is not appropriate.	Sep-26		

Specialist Only		Aripiprazole injection			Schizophrenia, rapid control of agitation and disturbed behaviours in patients, when oral therapy is not appropriate.	Oct-26		
Red		Arsenic trioxide		1,6	Acute promyelocytic leukaemia (relapsed/refractory)	May-24		
Red		Artesunate		1	Initial treatment of severe malaria in adults and children	Dec-24		
Red		Asciminib		1,6	Chronic myeloid leukaemia	May-24		
Red		Ascorbic Acid Injection/Infusion		1,6	Treatment of clinical vitamin C deficiency not amenable to dietary supply or oral replacement therapy in adults	May-24		
Red		Asenapine		1,6	Manic episodes (moderate to severe) associated with bipolar I disorder	May-24		
Red		Asfotase alfa		1,6	Hypophosphatasia - long term enzyme replacement therapy (ERT)	May-24		
Red		Asparaginase		1,6	Acute lymphoblastic leukaemia	May-24		
Red		Ataluren		1,6	Duchenne muscular dystrophy	May-24		
Red		Atazanavir (including combinations)		1,6	HIV Infection in combination with other antiretroviral drugs	May-24		
Red		Atezolizumab		6	In line with positive NICE TA recommendations	Apr-25		Atezolizumab NICE Information

Red		Atidarsagene autotemcel		1,6	Metachromatic leukodystrophy	May-24		
Red		Atovaquone		1,6		May-24		
Specialist only	Preferrerd -Hospital only- refer to local guidance where avaialble	Atropine injection			Emergency treatment of poisoning, treatment of bradycardia & use as anaesthesia	Sep-26		
Red		Autologous cell/blood related		1,6	In line with positive NICE TAs	Oct-24		Autologous NICE information
Red		Avacopan		1,6	NHSE commissioned.	May-24		
Red		Avalglucosidase alfa		1,6	Pompe disease	Apr-23	Apr-27	NICE TA821
Red		Avapritinib		1,6	Treating advanced systemic mastocytosis	Dec-24		Avapritinib NICE Information
Red		Avatrombopag		1,6	In line with positive NICE TA recommendations	May-24		Avatrombopag NICE Information
Red		Avelumab (including in combination)		1,6	As per licenced appropriate NICE TA	Jun-23		Avelumab NICE information
Red		Avibactam(including in combination with other drugs)		1	Antibiotic	Aug-24		
Red		Axicabtagene ciloleucel		1,6	In line with positive NICE TA recommendations	Jul-23		Axicabtagene ciloleucel NICE Information
Red		Axitinib		1,6	In line with positive NICE TAs	Oct-24		Axitinib NICE information
Red		Azacitidine		1,6	Myeloid leukaemia (Acute), Myelodysplastic syndromes. Chronic or Acute myelomonocytic leukaemia	May-24		
Red		Aztreonam		1,6				
Red		Aztreonam + avibactam		1	Antibiotic	Nov-24		
Red		Bacillus Calmette-Guerin	OncoTICE®	1,6	Bladder instillation			
Red		Baricitinib		1,6	In line with positive NICE TA recommendations	Dec-23		Baricitinib NICE information

Red		Baricitinib (dual classification)		1,3	Adults and children COVID-19 Treatment	Jun-23	Oct-25	NICE NG191
Red		Basiliximab		1,6	Renal transplantation (immunosuppressive therapy)	Jun-24		
Red		Bedaquiline		1,6	Tuberculosis	Jun-24		
Red		Bee Venom (Alutard Bee Venom®)		1,6	Allergy Immunotherapy	Jun-24		
Red		Belantamab mafodotin		1,6	In line with positive NICE TA recommendations	Jun-24		Belantamab mafodotin NICE Information
Red		Belatacept		1,6	Prophylaxis of graft rejection in adult recipients of a renal transplant	Jun-24		
Red		Belimumab		1,6	In line with positive NICE TA recommendations	Jun-24		Belimumab NICE information
Red		Belumosudil		1,6	In line with positive NICE TA recommendations	Feb-24		Belumosudil NICE information
Red		Belzutifan		6	In line with positive NICE TA recommendations	Jun-23		Belzutifan NICE Information
Red		Bendamustine		1,6	Chronic lymphocytic leukaemia, multiple myeloma	Jun-24		
Red		Benperidol		1	Antipsychotic	Feb-24		
Red		Benralizumab		1,6	In line with positive NICE TA recommendations	Jun-24		Benralizumab NICE Information
Red		Benzylpenicillin benzathine		1,6		Jun-24		
Red		Beractant		1,6	Pulmonary surfactants	Jun-24		
Red		Berotralstat		1,6	NHSE commissioned.	Jun-24		
Red		Beta Interferon		1,6		Jun-24		
Red		Betaine		1,6	Drugs used in metabolic disorders	Jun-24		

Red		Betamethasone injection		1,6	Status asthmaticus, shock from surgery/trauma, acute adrenal crisis, soft tissue lesions	Jun-24		
Red		Betula verrucosa		1	Treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen	Sep-25		NICE TA1087
Red		Bevacizumab		1,6	In line with positive NICE TA recommendations	Jun-23		Bevacizumab NICE information
Red		Bexarotene		1,6	Cutaneous T-cell lymphoma (CTCL) - skin manifestations of advanced stage	Jun-24		
Red		Bezlotoxumab		1,6	Prevention of recurrence of Clostridium difficile infection (CDI)	Jun-24		
Red		Bictegravir/emtricitabine/tenofovir alafenamide		1,6	Adults infected with human immunodeficiency virus-1 (HIV-1)	Jun-24		
Red		Bimekizumab		1	In line with positive NICE TA recommendations	Nov-23		Bimekizumab NICE information
Red		Binimetinib		1,6	In line with positive NICE TA recommendations			Binimetnib NICE information
Red		Birch bark extract	Filsuvez®	1,6	Treating epidermolysis bullosa	Oct-23		
Red		Bivalirudin		1,6				
Red		Bleomycin		1,6				
Red		Blinatumomab		1,6	In line with positive NICE TA recommendations	May-25		Blinatumomab NICE Information
Red		Bortezomib		1	In line with positive NICE TA recommendations	Sep-23		Bortezomib NICE information
Red		Bosentan		1	Pulmonary arterial hypertension & Systemic sclerosis with ongoing digital ulcer disease	Oct-23		

Red		Bosutinib		1,6	Chronic myeloid leukaemia	Jun-24		
Red		Botulinum toxin type A		1	In line with positive NICE TA recommendations	Sep-23		Botulinum toxin type A NICE information
Red		Brentuximab vedotin		1,6	in line with positive NICE TA Recommendations	Jun-25		Brentuximab+vedotin NICE Information
Red		Brexucabtagene autoleucel		1,6	Refractory B-cell acute lymphoblastic leukaemia	Jul-23		NICE TA893
Red		Brigatinib		1,6	Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	Jun-24		
Red		Brodalumab		1,6	Psoriasis (moderate to severe plaque) in adult patients who are candidates for systemic therapy.	Jun-24		
Red		Brolucizumab		1,6	Neovascular (wet) age-related macular degeneration (AMD)	Jun-24		
Red		Bromfenac		1,6	Ocular inflammation following cataract extraction in adults.	Jun-24		
Red		Budesonide 4mg m/r capsule	Kinpeygo®	1,6	Targeted-release budesonide for treating primary IgA nephropathy	Mar-26		NICE TA1128
Red		Budesonide orodispersible tablet	Jorveza®	1,6	In line with positive NICE TA recommendations	Jun-24		Budesonide Orodispersible tablet NICE information

Red		Bulevirtide		1,6	Treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adults with compensated liver disease	Jul-23		NICE TA896
Red		Bupivacaine		1,6	Local and surgical anaesthesia	Jun-24		
Red		Buprenorphine		1	Opioid dependence	Feb-26		
Red		Buprenorphine/Naloxone		1	Opioid drug dependance	Nov-25		Buprenorphine/naloxone NICE information
Red		Burosumab		1,6	In line with positive NICE TA recommendations	Oct-24		Burosumab NICE Information
Red		Buserelin		1,6	Infertility	Jul-24		
Red		Busulfan		1,6		Jul-24		
Red		C1 Esterase inhibitor		1,6	Acute hereditary angioedema	Jul-24		
Red		Cabazitaxel		1,6	In line with positive NICE TA recommendations	Jul-24		Cabazitaxel NICE Information
Red		Cabotegravir		1,6	In line with positive NICE TA recommendations	Jul-24		Cabotegravir NICE information
Red		Cabozantinib(including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Jul-24		Cabozantinib NICE Information
Red		Calcitonin (salmon)		1,6	Hypercalcaemia, Pagets disease,Bone pain in neoplastic disease, postmenopausal osteoporosis	Jul-24		
Red		Calcium Chloride injection		1,6	Emergency Treatment of Poisoning (calcium channel blockers or systemic effects of hydrofluoric acid)	Jul-24		
Red		Calcium Folinate		1,6		Jul-24		

Red		Calcium Gluconate		1,6		Jul-24		
Red		Calcium Polystyrene Sulfonate		1	All licensed indications	Feb-26		
Red		Canakinumab		1,6	NHSE Commissioned	Jul-24		
Red		Cannabidiol		1,6	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Red		Cannabinoids		1	In line with positive NICE TA recommendations	Dec-23		Cannabidiol NICE information
Red		Capecitabine		1,6	In line with positive NICE TA recommendations	Jul-24		Capecitabine NICE Information
Red		Capivasertib (in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Jun-25		Capivasertib NICE Information
Red		Caplacizumab		1,6	In line with positive NICE TA recommendations	Jul-24		Caplacizumab NICE Information
Red		Capreomycin			Tuberculosis	Aug-24		
Red		Capsaicin Patch	Qutenza®	1	Peripheral neuropathic pain	Sep-23		
Red		Carbetocin		1,6	Uterine atony and postpartum haemorrhage after Caesarian section(prevention of)	Jul-24		
Red		Carboplatin		1,6	In line with positive NICE TA recommendations	Jul-24		
Red		Carboprost		1,6	Post-partum haemorrhage	Jul-24		
Red		Carfilzomib		1,6	In line with positive NICE TA recommendations	Jul-24		
Red		Carglumic acid		1,6	Drugs used in metabolic disorders	Jul-24		
Red		Cariprazine		1	Antipsychotic	Feb-24		
Red		Carmustine		1,6	In line with positive NICE TA recommendations	Jul-24		Carmustine NICE Information
Red		Carnitine		1,6	Carnitine deficiency	Jul-24		
Red		Caspofungin		1,6	Antifungal	Jul-24		

Red		Catridecacog		1,6	Long term prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency and treatment of breakthrough bleeding episodes during regular prophylaxis	Jul-24		
Red		Cefazolin		1,6	Treatment of skin/soft tissue infections and bone/joint infections	Jul-24		
Red		Cefepime		1,6	Treatment of infections caused by bacteria that are cefepime-sensitive	Jul-24		
Red		Cefepime + enmetazobactam		1	Antibiotic	Aug-24		
Red		Cefiderocol		1,6	Infections due to aerobic Gram-negative organisms	Jul-24		
Red		Cefixime		1	Antibacterial	Feb-24		
Red		Cefoxitin		1,6	Antibiotic	Jul-24		
Red		Ceftaroline fosamil		1,6	Infection - complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP) in adults	Jul-24		
Red		Ceftazidime (including in combination with other drugs)		1	Antibiotic	Aug-24		
Red		Ceftobiprole		1,	Antibiotic	Aug-24		
Red		Ceftolozane (including in combination with other drugs)		1,	Antibiotic	Aug-24		
Red		Cefuroxime eye drops and injections		1	Miscellaneous ophthalmic preparations	Aug-24		

Specialist only		Cemiplimab			In line with positive NICE TA recommendations	Sep-26		Cemiplimab NICE Information
Red		Cenobamate (in children only)		7	Epilepsy	May-24		
Red		Ceritinib		1,6	In line with positive NICE TA recommendations	Aug-24		Ceritinib NICE information
Red		Certolizumab		1,6	In line with positive NICE TA recommendations	Aug-24		Certolizumab NICE Information
Red		Cetrorelix		1	Treatment of female infertility	Aug-24		
Red		Cetuximab		1,6	In line with positive NICE TA recommendations	Aug-24		Cetuximab NICE Information
Red		Chlorambucil		1		Aug-24		
Red		Chloramphenicol (oral or injectables)		1		Aug-24		
Specialist only		Chlordiazepoxide **Traffic lighted specialist only in Barnsley,Doncaster & Sheffield** (Traffic Lighted specialist advice for Rotherham only)			Alcohol withdrawal	Oct-26		
Red		Chlormethine hydrochloride		1,6		Aug-24		
Red		Chloroquine			For malaria prophylaxis is grey, for treatment of malaria and other indications is red.	Aug-24		
Red		Chlorothiazide		1,6	Unlicensed special. Used in BHNFT (paediatrics)	Aug-24		
Red		Chorionic Gonadotrophin		1,6	Infertility.	Aug-24		
Red		Cidofovir		1,6	Cytomegalovirus infection in immunocompromised patients	Aug-24		

Specialist Only		Cinacalcet (dual categorisation)			Secondary hyperparathyroidism in adult patients with end stage renal disease Also see Shared care entry.	Oct-26		
Red		Cipaglucosidase alfa		1	In line with positive NICE TA recommendations	Sep-23		Cipaglucosidase NICE information
Red		Ciprofloxacin eye drops		1	Miscellaneous ophthalmic preparations	Aug-24		
Red		Cisplatin		1,6	In line with positive NICE TA recommendations	Aug-24		Cisplatin NICE Information
Red		Cladribine (all formulations)		1,6	In line with positive NICE TA recommendations	Aug-24		Cladribine NICE information
Specialist only	Preferred -Hospital only	Clesrovimab			Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.	Sep-26		
Specialist Only		Clindamycin - solution for infusion or injection			For use in line with hospital antimicrobial policies	Oct-26		
Red		Clobazam		1	Anxiety (severe- short-term relief)	Feb-26		
Red		Clofarabine		1,6	Acute lymphoblastic leukaemia	Aug-24		
Red		Clofazimine		1,6	Leprosy	Aug-24		
Red		Clozapine				Dec-25		
Red		Cobicistat (including combinations)		1,6	NHSE commissioned.	Aug-24		
Red		Co-careldopa intestinal gel	Duodopa®	1,6	Parkinson's Disease	Jul-23		

Specialist Only		Colistimethate sodium (colistin sulfomethate sodium) (dual categorisation)			Specialised commissioning. To be prescribed by cystic fibrosis services. See shared care category for non-cystic fibrosis bronchiectasis,	Oct-26		
Red		Conestat alfa		1,6	Angioedema (hereditary)	Aug-24		
Red		Copper histidinate injections	Copper histidinate injections	1	Presymptomatic neonates with classical Menkes disease	May-26		
Specialist Only		Crisantaspase			Acute lymphoblastic leukaemia	Oct-26		
Red		Crizotinib		1,6	In line with positive NICE TA recommendations	Aug-24		Crizotinib NICE Information
Red		Crovalimab		1,6	In line with positive NICE TA recommendations	Feb-25		Crovalimab NICE Information
Red		Cyclophosphamide		1,6	Cancer chemotherapy	Aug-24		
Red		Cycloserine		1		Aug-24		
Red		Cyproheptadine		1	Emergency Treatment of Poisoning (Serotonin Syndrome)	Aug-24		
Specialist Only		Cyproterone Acetate			Male hypersexuality/ Anti-androgen used in the treatment of severe hypersexuality and sexual deviation in the male.	Oct-26		
Red		Cytarabine (including in combination with other drugs)		1		Aug-24		
Red		Dabrafenib (including in combination with other drugs)		1	In line with positive NICE TA recommendations	Sep-23		Dabrafenib NICE information
Red		Dacomitinib		1,6	In line with positive NICE TA recommendations	Oct-24		Dacomitinib NICE information
Red		Dactinomycin		1,6	Paediatric cancers	Oct-24		

Red		Dalbavancin		1,6	Glycopeptide antibacterial	Oct-24		
Specialist Only		Danaparoid sodium			Heparinoids	Oct-26		
Red		Danicopan with ravulizumab or eculizumab		1,6	In line with positive NICE TA recommendations	Nov-24		Danicopan NICE Information
Red		Dapsone (dual classification)		1	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP	Nov-24		
Red		Daptomycin		1	Lipopeptide antibacterial	Oct-24		
Red		Daratumumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Sep-23		Daratumumab NICE information (also used with dexamethasone and Lenalidomide)
Red		Darcarbazine		1	Melanoma,Soft-tissue sarcomas,Hodgkin's disease	Oct-24		
Red		Darolutamide (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-24		Darolutamide NICE Information
Red		Darunavir (including in combination)		1	HIV infection	Oct-24		
Red		Dasabuvir		1,6	Chronic hepatitis C	Nov-24		
Red		Dasatinib		1,6	In line with positive NICE TA recommendations	Oct-24		Dasatinib NICE information
Red		Daunorubicin		1,6	In line with positive NICE TA recommendations	Oct-24		Daunorubicin NICE Information
Red		Deferasirox		1	Iron overload	Oct-24		
Red		Deferiprone		1	Iron overload in patients with thalassaemia major	Oct-24		
Red		Delafloxacin		1,6	Fluoroquinolone antibiotic	Apr-25		
Red		Delamanid		2	Pulmonary multi drug resistant TB	Nov-24		

Red		Delgocitinib		1,6	Treating moderate to severe chronic hand eczema	Dec-25		NICE TA1107
Red		Denosumab 120mg injection	XGEVA	1	In line with NICE TA 549 and NICE TA265	Sep-23		Denosumab NICE TA549 & TA 265 information
Red		Dequalinium chloride vaginal tablets		1	Bacterial vaginosis	Sep-23		
Red		Deucravacitinib		1,6	Treating moderate to severe plaque psoriasis	Sep-23		
Specialist only		Deuruxolitinib			For treating severe alopecia areata	Sep-26		NICE TA1178
Red		Deutivacaftor + tezacaftor + vanzacaftor		1,6	Cystic fibrosis	Sep-25		NICE TA1085
Red		Dexamethasone and levofloxacin eye drops		1	Prevention of infection associated with cataract surgery in adults	Sep-23		
Red		Dienogest			Endometriosis	Jul-26		
Red		Digoxin specific antibody fragments		1,6	Management of digoxin toxicity	Apr-25		
Red		Diloxanide		1,6	Antiprotozoal drugs - amoebicides	Apr-25		
Red		Dimethyl fumarate		1,6	In line with positive NICE TA recommendations	Apr-25		Dimethyl+fumarate NICE information
Red		Dinoprostone		1,6	Induction of labour	Apr-25		
Red		Dinutuximab		1,6	In line with positive NICE TA recommendations	Apr-25		Dinutuximab NICE Information
Red		Diroximel		1,6	Multiple sclerosis (MS) relapsing-remitting	Apr-25		
Red		Disodium Pamidronate		1,6	Hypercalcaemia, Paget's Disease	Apr-25		
Red		Disopyramide		1,6	All licensed indications	Mar-26		

Specialist Only		Disulfiram **Traffic lighted specialist only in Doncaster** (Traffic Lighted specialist initation & shared care in other Places)			Alcohol disorders	Oct-26		
Red		Dobutamine		1,6	Inotropic Sympathomimetics	Apr-25		
Red		Docetaxel		1,6	In line with positive NICE TA recommendations	Apr-25		Docetaxel NICE Information
Red		Dolutegravir (including combinations)		1,6	HIV	Apr-25		
Specialist only		Donidalorsen			Preventing recurrent attacks of hereditary angioedema in people 12 years and over	Sep-26		NICE TA1183
Red		Doravirine (including in combination)		1,6	HIV	May-25		
Red		Dornase alfa		1,6		Jul-24		
Specialist Only		Dostarlimab			In line with positive NICE TA recommendations	Oct-26		Dostarlimab NICE Information
Red		Doxapram Hydrochloride		1,6	Postoperative respiratory depression/Acute respiratory failure	May-25		
Red		Doxorubicin		1,6	In line with positive NICE TA recommendations	May-25		Doxorubicin NICE Information
Red		Dronedarone		1	Atrial fibrillation			NICE TA197
Red		Droperidol		1	Prevention and treatment of postoperative nausea and vomiting	May-25		

Red		Dupilumab		1,6	In line with positive NICE TA recommendations	Jul-26		Dupilumab NICE information
Specialist Only		Durvalumab (including in combination with other drugs)			In line with positive NICE TA recommendations	Oct-26		Durvalumab NICE information also used in combination with other drugs
Red		Eculizumab		1,6	In line with positive NICE TA recommendations	Apr-24		Eculizumab NICE Information
Red		Efanesoctocog alfa			Treatment and prophylaxis of bleeding in patients aged ≥2 years with severe or moderate haemophilia A (≤5% endogenous plasma factor VIII activity)	May-25		NICE TA1051
Red		Efavirenz (including in combination)		1,6	HIV	May-25		
Red		Efmoroctocog alfa		1,6	Used to treat bleeding disorders	May-25		
Red		Eladocagene exuparvovec		1,6	Treatment of patients aged ≥18 months with a clinical, molecular and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase deficiency with a severe phenotype	Dec-23		
Red		Elafibranor		1,6	for previously treated primary biliary cholangitis	Dec-24		
Red		Elbasvir-grazoprevir		1,6	In line with positive NICE TA recommendations	May-25		Elbasvir-grazoprevir NICE information
Red		Elosulfase alfa		1,6	Mucopolysaccharidosis type 4A	May-25		Elosulfase+alfa NICE Information
Red		Elranatamab		1,6	In line with positive NICE TA recommendations	Jan-25		Elranatamab NICE Information

Red		Eltrombopag olamine		1	Treating chronic immune thrombocytopenia in adults	Sep-23		NICE TA293
Red		Elvitegravir (including combinations)		1,6	HIV	May-25		
Red		Emicizumab		1,6	Prophylaxis of haemorrhage in haemophilia A	May-25		
Red		Emtricitabine (including combinations)		1,6	HIV	May-25		
Red		Encorafenib		1,6	In line with positive NICE TA recommendations	May-25		Encorafenib NICE Information
Red		Enfortumab vedotin (including combinations)		1,6	In line with positive NICE TA recommendations	Oct-25		Enfortumab+vedotin NICE Information
Red		Enfuvirtide		1,6	HIV	May-25		
Red		Entecavir		1,6	In line with positive NICE TA recommendations	Jun-25		Entecavir NICE Information
Red		Entrectinib		1,6	In line with positive NICE TA recommendations	Jun-25		Entrectinib NICE information
Red		Enzalutamide		1	In line with positive NICE TA recommendations	Sep-23		Enzalutamide NICE information
Red		Epcoritamab		1,6	In line with positive NICE TA recommendations	Apr-24		Epcoritamab NICE Information
Red		Ephedrine 30mg/10ml and 30mg/ml injection		1	Vasoconstrictor Sympathomimetics	Jun-25		
Red		Epirubicin		1	Cancer - breast (Advanced or metastatic) Cancer - Colorectal (metastatic)	Jun-25		
Red		Eplontersen		1,6	In line with positive NICE TA recommendations	Jan-25		Eplontersen NICE Information

Red		Epoetin Alfa		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25		Epoetin alfa NICE information
Red		Epoetin Beta		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25		Epoetin Beta NICE information
Red		Epoetin Zeta		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25		
Red		Epoprostenol		1,6	pulmonary arterial hypertension, to prevent blood clotting during kidney dialysis in emergency situations	Jul-25		
Red		Eptacog alfa (activated)	(NovoSeven®)	1,6	Treatment of severe postpartum haemorrhage	Jun-25		
Red		Eptacog beta	(Cevenfacta®) (activated)	1,6	Treatment of bleeding episodes and for the prevention of bleeding: in patients with congenital haemophilia	Jun-25		
Red		Eptifibatide		1	In line with positive NICE TA recommendations	Jun-25		Eptifibatide NICE information
Red		Eptinezumab		1	Migraine	Sep-23		NICE TA871
Red		Eravacycline	(Xerava®)	1	Complicated intra-abdominal infections in adults	Jun-25		
Red		Erdafitinib		1,6	In line with positive NICE TA recommendations	Jun-25		Erdafitinib NICE Information
Red		Erenumab		1,3	Migraines in adults			NICE TA682
Red		Ergometrine		1	Postpartum haemorrhage caused by uterine atony	Jun-25		
Red		Eribulin		1,6	In line with positive NICE TA recommendations	Jun-25		Eribulin NICE information
Red		Erlotinib		1	In line with positive NICE TA recommendations	Sep-23		Erlotinib NICE information
Red		Ertapenem		1	Carbapenems	Jun-25		

Red		Esketamine solution for injection/infusion		1	Anaesthesia and pain relief (analgesia)	Jun-25		
Red		Eslicarbazepine (in children only)		7	Epilepsy	May-24		
Red		Esmolol	(Brevibloc®)	1	Beta-adrenoceptor blocking drugs	Jun-25		
Red		Etanercept		1,6	In line with positive NICE TA recommendations	Jul-25		Etanercept NICE information
Red		Etelcalcetide		1	In line with positive NICE TA recommendations	Jul-25		Etelcalcetide NICE information
Red		Etoposide		1	In line with positive NICE TA recommendations	Jul-25		Etoposide NICE information
Red		Etranacogene dezaparvovec		1,6	Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B	Oct-24		
Red		Etrasimod		1,6	moderately to severely active ulcerative colitis in people aged 16 and over	Jun-24		
Red		Etravirine		1,6	HIV infection.	Jul-25		
Red		European Viper Venom Antiserum		1	European Adder bite	Jul-25		
Red		Everolimus		1	In line with positive NICE TA recommendations	Sep-23		Everolimus NICE information
Red		Evolocumab		1,6	In line with positive NICE TA recommendations	Jul-25		Evolocumab NICE information
Red		Ex vivo expanded autologous human corneal epithelial cells containing stem cells	(Holoclar®)	1,6	In line with positive NICE TA recommendations	Jul-25		Holoclar NICE information
Red		Exagamglogene autotemcel		1,6	In line with positive NICE TA recommendations	Oct-24		Exagamglogene+autotemcel NICE Information
Red		Ezetimibe in children		7	Statin	Feb-24		

Red		Factor VIIa, Factor VIII, Factor IX, Factor XIII		1,6	Haemorrhage in patients with haemophilia A or B with antibodies to factors VIII or IX, acquired haemophilia, factor VII deficiency, or Glanzmann's thrombasthenia	Jul-25		
Red		Faricimab		1,6	In line with positive NICE TA recommendations	Oct-24		Faricimab NICE Information
Red		Fedratinib		1,6	In line with positive NICE TA recommendations	Jul-25		Fedratinib NICE information
Red		Felbamate		1	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Red		Fenfluramine		1,6	In line with positive NICE TA recommendations	May-25		Fenfluramine NICE Information
Red		Ferric carboxymaltose		1	Iron deficiency when oral iron preparations are ineffective or cannot be used.	Jul-25		
Red		Fezolinetant		1,6	Treating moderate to severe vasomotor symptoms associated with menopause	May-26		NICE TA 1143
Red		Fibrin sealants		1	Treatment and prophylaxis of haemorrhage	Jul-25		
Red		Fibrinogen		1,6	As per BCSH guidelines for specialist indications	Jul-25		
Red		Filgotinib		1	In line with positive NICE TA recommendations	Jul-25		Filgotinib NICE information
Red		Filgrastim		1	Neutropenia	Jul-25		
Red		Fingolimod		1,6	In line with positive NICE TA recommendations	Jul-25		Fingolimod NICE information
Red		Fludarabine		1	In line with positive NICE TA recommendations	Sep-23		Fludarabine NICE information

Red		Fluocinolone acetonide		1,6	Chronic diabetic macular oedema	Apr-24		
Red		Fluocinolone acetonide intravitreal implant	(Iluvien®)	1	In line with positive NICE TA recommendations	Jul-25		Fluocinolone acetonide intravitreal implant NICE information
Red		Fluoride tablets		6	Dental indications	Sep-23		
Red		Follitropin alfa, beta, delta & Follitropin alfa/lutropin alfa		1	IVF	Jul-25		
Red		Fomepizole		1	Emergency Treatment of Poisoning (ethylene glycol or methanol poisoning)	Jul-25		
Red		Fondaparinux		1	Acute coronary syndromes, NSTEMi, angina	Jul-25		
Red		Fosamprenavir		1,6	HIV infection.	Jul-25		
Red		Fosaprepitant		1	Chemotherapy-associated nausea and vomiting	Aug-25		
Red		Foslevodopa–foscarbidopa		1,6	Advanced Parkinson's with motor symptoms	Feb-24		NICE Information
Red		Fostamatinib		1	Treating refractory chronic immune thrombocytopenia	Aug-25		NICE TA 835
Red		Fostemsavir		1,6	HIV in combination with other anti-retroviral drugs	Aug-25		
Red		Fremanezumab		1	As per licenced appropriate NICE TA	Sep-23		Fremanezumab NICE information
Red		Fruquintinib		1,6	Previously treated metastatic colorectal cancer	Aug-25		NICE TA 1079
Red		Fulvestrant		1	In line with positive NICE TA recommendations	Sep-23		Fulvestrant NICE information

Red		Futibatinib		1,6	Treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy	Jan-26		Futibatinib NICE Information
Red		Galcanezumab		1	Migraine prevention	Aug-25		NICE TA659
Red		Galsulfase		1,6	Mucopolysaccharidosis	Aug-25		
Red		Ganciclovir eye drops		1,6	All licensed indications	Mar-26		
Red		Garadacimab		1,6	Preventing recurrent attacks of hereditary angioedema in people 12 years and over	Nov-25		NICE TA1101
Red		Gefitinib		1	In line with positive NICE TA recommendations	Sep-23		Gefitinib NICE information
Red		Gelatin	(Gelaspan®)	1,5	Plasma substitute	Apr-26		
Red		Gemcitabine		1	In line with positive NICE TA recommendations	Sep-23		Gemcitabine NICE information
Red		Gemtuzumab		1,6	Untreated acute myeloid leukaemia (AML)	Aug-25		NICE TA545
Red		Gilteritinib		1,6	Treatment of relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.	Aug-25		NICE TA642
Red		Givinostat		1,6	Treating Duchenne muscular dystrophy in people 6 years and over	Jul-26		NICE TA 1157
Red		Glatiramer		1,6	Multiple Sclerosis	Aug-25		NICE TA527
Red		Glecaprevir/Pibrentasvir		1,6	Chronic hepatitis C	Aug-25		NICE TA499

Red		Glibenclamide suspension	Amglidia®	1	Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.	May-26		
Red		Glofitamab		1,6	In line with positive NICE TA recommendations	Nov-23		Glofitamab NICE Information
Red		Glucarpidase		1,6	To reduce toxic plasma methotrexate concentration in adults and children (aged ≥28 days) with delayed methotrexate elimination	Dec-23		
Red		Golimumab		1	In line with positive NICE TA recommendations	Aug-25		Golimumab NICE information
Red		Green Tea Leaves extract ointment (Camellia sinensis)		1,6	Warts - genital and perianal	Jul-24		
Red		Guselkumab		1,6	In line with positive NICE TA recommendations	Aug-25		Guselkumab NICE Information
Red		Human coagulation factor VIII, human Von Willebrand factor		1,6	Haemophilia A and Von Willebrand disease- prevention and treatment of bleeding	Sep-25		
Red		Human coagulation factor X		1,6	Prophylaxis of bleeding in patients with hereditary factor X deficiency	Sep-25		
Red		Human hepatitis B immunoglobulin		1	All licenced indications	Sep-25		
Red		Human Menopausal Gonadotrophins (Menotrophin)		1	All licensed indications	Sep-25		
Red		Human normal immunoglobulin		1,6	Multiple indications	Sep-25		Immunoglobulin supporting information
Red		Hybrid closed loop systems		1,6	Managing blood glucose levels in type 1 diabetes	Feb-24		
Red		Hydroxocobalamin (dual traffic light)		1	Emergency Treatment of Poisoning (cyanide)	Sep-25		

Red		Hydroxycarbamide		1	All licensed indications	Sep-25		
Specialist Only		Ibrutinib			In line with positive NICE TA recommendations	Oct-26		Ibrutinib NICE information
Red		Icatibant		1,6	Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency	Sep-25		
Red		Idarubicin		1	Acute non-lymphocytic leukaemia, advanced breast cancer. Acute myeloid leukaemia in children , in combination with cytarabine, for remission induction.	Sep-25		
Red		Idarucizumab		1	Rapid reversal of anticoagulant effect of dabigatran	Sep-25		
Red		Idebenone		1,6	Visual impairment in patients with Leber's Hereditary Optic Neuropathy (LHON)	Sep-25		NICE TA1093
Red		Idelalisib		1	In line with positive NICE TA recommendations	Oct-23		Idelalisib NICE information
Red		Idursulfase		1,6	Hunter syndrome (Mucopolysaccharidosis II)	Sep-25		
Red		Iloprost		1	All licensed indications	Sep-25		
Red		Imatinib		1,6	In line with positive NICE TA recommendations	Sep-25		Imatinib NICE information
Red		Imiglucerase		1,6	Drugs used in metabolic disorders/Gauchers disease	Sep-25		
Red		Imlifidase		1,6	In line with positive NICE TA recommendations	Sep-25		Imlifidase NICE information
Red		Infliximab (including biosimilar)		1,6	In line with positive NICE TA recommendations	Sep-25		Infliximab NICE information

Red		Inosine pranobex		1	Herpes simplex	Sep-25		
Red		Inotersen		1,6	In line with positive NICE recommendations	Sep-25		Inotersen NICE information
Red		Interferon Alfa, Beta 1a & 1b,		1,6	In line with positive NICE TA recommendations	Sep-25		Interferon NICE information
Red		Ipilimumab		1,6	In line with positive NICE TA recommendations	Sep-25		Ipilimumab NICE information
Red		Iptacopan		1,6	Paroxysmal nocturnal haemoglobinuria	Oct-24		Iptacopan NICE Information
Specialist Only		Isatuximab(including in combination)		1,6	In line with positive NICE TA recommendations	Sep-25		Isatuximab NICE information
Red		Isavuconazole		1,6	Invasive aspergillosis. Mucormycosis	Sep-25		
Red		Isocarboxazid		1	Depressive illness	Sep-25		
Red		Isoprenaline Sulfate		1	Inotropic Sympathomimetics	Sep-25		
Red		Isosorbide dinitrate injection		1,5	Emergency Treatment of Poisoning (hypertension)	Apr-26		
Red		Isotretinoin		1	Acne	Sep-25		
Red		IV nutrition products		1,5	Intravenous nutrition	Apr-26		
Red		Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor			In line with positive NICE TA recommendations	Oct-24		NICE TA988
Red		Ivermectin 3mg tablets (dual traffic light status)		1	Red Traffic Light Status for all other indications Green for scabies treatment	Nov-24		
Red		Ivosidenib(including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Feb-24		Ivosidenib NICE information
Red		Ixazomib		1,6	In line with positive NICE TA recommendations	Oct-25		Ixazomib NICE information
Red		Ixekizumab		1	In line with positive NICE TA recommendations	Oct-25		Ixekizumab NICE information

Red		Ketamine		1,6	All licensed indications	Mar-26		Ketamine BNF Information
Red		Ketoconazole tablets		1	Cushing's syndrome	Oct-23		
Red		Lamivudine		1	For all indications	Oct-25		
Red		Lanadelumab		1,6	In line with positive NICE TA recommendations	Oct-25		Lanadelumab NICE information
Red		Landiolol hydrochloride		1,5	Supraventricular tachycardia and for the rapid control of ventricular rate	Apr-23		
Red		Lanreotide		1,6	All licensed indications	Mar-26		Lanreotide BNF Information
Red		Lanthanum		1	In line with NICE guidance	Oct-25		Lanthanum NICE information
Red		Lapatinib		1,6	In line with positive NICE TA recommendations	Oct-25		Lapatinib NICE information
Red		Laronidase		1,6	Mucopolysaccharidosis	Oct-25		
Red		Larotrectinib sulphate		1,6	In line with positive NICE TA recommendations	Oct-23		Larotrectinib NICE information
Red		Lebrikizumab		1,6	In line with positive NICE TAs	Aug-24		Lebrikizumab NICE Information
Red		Ledipasvi/Sofosbuvir		1,6	Hepatitis C	Oct-25		
Red		Lenacapavir		1,6	HIV infection	Sep-23		
Red		Lenalidomide		1,6	In line with positive NICE TA recommendations	Oct-25		Lenalidomide NICE information
Red		Leniolisib		1,6	Treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over	May-25		NICE HST33
Red		Lenograstim		1	All licensed indications	Oct-25		
Red		Lenvatinib		1	In line with positive NICE TA recommendations	Sep-23		Lenvatinib NICE information
Red		Letermovir		1,6	In line with positive NICE TA recommendations	Oct-25		Letermovir NICE information
Red		Levocarnitine		1	All licensed indications	Oct-25		Lenograstim BNF Information

Red		Levodopa + carbidopa + entacapone	Lecigon®	1,6	Treatment of advanced Parkinson´s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results	Dec-24		
Red		Levofloxacin- Infusion, solution for infusion, nebuliser liquid & eye drops		1,6	All licensed indications	Mar-26		Levofloxacin BNF Information
Red		Levothyroxine injection		1	Myxoedema coma and hypothyroidism in patients where oral therapy is not feasible, particularly due to difficulties in swallowing or malabsorption	Dec-23		
Red		Linezolid **Traffic Lighted Red only in Barnsley,Doncaster & Sheffield** (Traffic Lighted Green in Rotherham)			oxazolidinone antibacterial	Jul-26		
Red		Linzagolix		1	In line with positive NICE TA recommendations	Jul-25		Linzagolix NICE Information
Red		Lipegfilgrastim		1	All licensed indications	Oct-25		
Red		Liraglutide	Saxenda®	1,6	Weight loss	Oct-23		NICE TA664
Red		Lisocabtagene maraleucel		1,6	In line with positive NICE TA recommendations	May-25		Lisocabtagene+maraleucel NICE Information

Red		Lisocabtagene maraleucel		1,6	Relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment	Jul-26		NICE TA1159
Red		Lomitapide		1	An inhibitor of microsomal triglyceride transfer protein (MTP)	Oct-23		
Red		Lomustine		1	All licensed indications	Oct-25		
Red		Loncastuximab tesirine		1,6	In line with positive NICE TA recommendations	Feb-24		Loncastuximab+tesirine NICE information
Red		Lopinavir/Ritonavir		1	All licensed indications	Oct-25		
Red		Lorlatinib		1,6	In line with positive NICE TA recommendations	Sep-23		Lorlatinib NICE information
Specialist Only		L-Ornithine-L-aspartate (LOLA)			For acute overt hepatic encephalopathy	Oct-26		
Red		Loteprednol eye drops		1	Corticosteroid eye drops	May-26		
Red		L-Tryptophan		1,5	Adults with treatment-resistant depression following unsuccessful trial of standard antidepressants and as an adjunct to other anti-depressant medications	May-24		
Red		Lumacaftor/Ivacaftor		1,6	Treatment for cystic fibrosis	Oct-24		Lumacaftor/Ivacaftor NICE Information
Red		Lumasiran		1,6	Treatment of primary hyperoxaluria type 1 in all age groups	Sep-23		
Red		Lurasidone		1	All licensed indications	Oct-25		
Red		Lusutrombopag		1	In line with positive NICE TA recommendations	Oct-25		Lusutrombopag NICE information
Red		Macitentan		1,6	All licensed indications	Oct-25		

Red		Magnesium carbonate/Anhydrous citric acid			Bowel cleansing prior to bowel endoscopy, radiology, or colonic surgery	Jun-26		
Red		Mannitol		1,6	In line with positive NICE TA recommendations	Oct-25		Mannitol NICE information
Red		Maraviroc		1,6	All licensed indications	Oct-25		
Red		Maribavir		1,6	In line with positive NICE TA recommendations	Oct-25		Maribavir NICE information
Red		Marstacimab		1	Routine prophylaxis of bleeding episodes in patients with haemophilia	Aug-25		NICE TA1073
Red		Mavacamten		1,6	Treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3	Oct-23		NICE TA913
Red		Mecasermin		1	All licensed indications	Oct-25		
Red		Mepacrine		1	All licensed indications	Oct-25		
Specialist only		Mepolizumab			In line with positive NICE TA recommendations	Sep-26		Mepolizumab NICE Information
Red		Mercaptamine		1,6	All licensed indications	Oct-25		
Red		Meropenem		1	All licensed indications	Oct-25		
Red		Mesna		1	All licensed indications	Oct-25		
Red		Metaraminol		1	Acute hypotension	Jul-26		Metaraminol Information
Red		Methoxyflurane		1	All licensed indications	Oct-25		
Red		Methoxypsoralen (Also known as methoxsalen)		1	Dermatology specialist only	Jul-26		
Red		Methsuximide		1	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Red		Methyl-5-Aminolevulinate	Metvix®	1	Actinic keratoses, basal cell carcinoma, squamous cell carcinoma in situ (Bowen´s disease)	Jul-26		Photodamage NICE Information
Red		Metreleptin		1,6	In line with NICE recommendations	Oct-25		Metreleptin NICE information
Red		Metyrapone		1,6	Cushing's syndrome	Jun-24		
Red		Mexiletine		1,6	All licensed indications	Oct-25		Mexiletine NICE information
Red		Midostaurin		1,6	In line with positive NICE TA recommendations	Oct-25		Midostaurin NICE information
Red		Mifamurtide		1,6	In line with positive NICE TA recommendations	Oct-25		Mifamurtide NICE information
Red		mifepristone (includes in combination)		1	All licensed indications	Oct-25		
Red		Migalastat		1,6	In line with NICE recommendations	Oct-25		Migalastat NICE information
Red		Miglustat		1	In line with positive NICE TA recommendations	Sep-23		Miglustat information
Specialist Only		Mirdametinib			In line with positive NICE TA recommendations	Oct-26		Mirdametinib NICE Information
Red		Mirikizumab		1,6	In line with positive NICE TA recommendations	Aug-25		Mirikizumab NICE Information
Specialist only		Mirvetuximab soravtansine			In line with positive NICE TA recommendations	Sep-26		NICE TA 1169
Red		Misoprostol (includes in combination)(multiple traffic light classifications)		1	Induction of labour or miscarriage or abortion	Oct-25		
Red		Mitomycin		1	All licensed indications	Oct-25		
Red		Mitotane		1	All licensed indications	Oct-25		
Red		Mitoxantrone		1	All licensed indications	Oct-25		
Red		Mogamulizumab		1,6	In line with positive NICE TA recommendations	Oct-25		Mogamulizumab NICE information

Red		Molnupiravir		1	Treating COVID-19	May-25		NICE TA1056
Red		Momelotinib		1,6	Myelofibrosis-related splenomegaly or symptoms	May-24		
Red		Morphine Sulphate 100 microgram/ml oral solution		1	Opioid	Oct-23		
Specialist only	Preferred - Only via sexual health clinics in line with national guidelines	Mpox vaccine	Imvanex®		Active immunisation against mpox, smallpox and disease caused by vaccinia virus in adults.	Sep-26		Smallpox and mpox: the green book
Red		Mycophenolate (dual traffic light classification)		1	Red for all other indications and TLS Amber for shared care protocols	Aug-24		
Red		Natalizumab		1,6	In line with positive NICE TA recommendations	Nov-23		Natalizumab NICE information
Red		Nelarabine		1,6	T-cell acute lymphoblastic leukaemia, T-cell lymphoblastic lymphoma	Jul-26		Nelarabine information
Red		Nelfinavir		1,5,6	HIV	Oct-25		
Specialist Only		Nemolizumab			In line with positive NICE TA recommendations	Oct-26		Nemolizumab NICE Information
Red		Nepafenac		1	All licensed indications	Oct-25		
Red		Neratinib		1,6	In line with positive NICE TA recommendations	Oct-25		Neratinib NICE information
Red		Nevirapine		1,6	All licensed indications	Oct-25		
Red		Nilotinib		1,6	In line with positive NICE TA recommendations	Oct-25		Nilotinib NICE information
Red		Nimodipine		1	All licensed indications	Oct-25		
Red		Nintedanib		1,6	In line with positive NICE TA recommendations	Oct-25		Nintedanib NICE information
Red		Niraparib		1,6	In line with positive NICE TA recommendations	Mar-26		Niraparib NICE Information

Red		Nirmatrelvir plus Ritonavir	Paxlovid®	1,3	COVID-19 Treatment	Jun-23		
Red		Nirmatrelvir plus ritonavir and tocilizumab		1,5	for treating COVID-19	Apr-26		
Red		Nirsevimab		1,6	Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season	Nov-25		
Red		Nitisinone		1,6	All licensed indications	Oct-25		
Red		Nivolumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Feb-24		Nivolumab NICE Information
Red		Noradrenaline		1	All licensed indications	Oct-25		
Red		Nusinersen (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25		Nusinersen NICE information
Red		Obecabtagene autoleucel		1,6	Relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in line with positive NICE TA	Jan-26		Obecabtagene autoleucel NICE Information
Red		Obeticholic acid		1,6	In line with positive NICE TA recommendations	Oct-25		Obeticholic acid NICE information
Red		Obinutuzumab		1,6	In line with positive NICE TA recommendations	Oct-25		Obinutuzumab NICE information
Red		Ocrelizumab		1,6	In line with positive NICE TA recommendations	Oct-25		Ocrelizumab NICE information
Red		Ofatumumab		1	In line with positive NICE TA recommendations	Nov-23		Ofatumumab NICE information

Red		Olaparib (can be given with bevacizumab & abriraterone)		1,6	In line with positive NICE TA recommendations	Sep-23		Olaparib NICE information
Red		Omalizumab		1,6	In line with positive NICE TA recommendations	Oct-25		Omalizumab NICE information
Red		Ombitasvir, paritaprevir and ritonavir		1,6	In line with positive NICE TA recommendations	Oct-25		Ombitasvir/paritaprevir/ritonavir NICE information
Red		Osimertinib		1,6	In line with positive NICE TA recommendations	Apr-25		Osimertinib NICE Information
Red		Oxaliplatin		1	In line with positive NICE TA recommendations	Oct-25		Oxaliplatin NICE information
Red		Oxybutynin intravesical solution		6	Indicated for the suppression of neurogenic detrusor overactivity (NDO) in children from 6 years of age and adults, who are managing bladder emptying by clean intermittent catheterisation, not adequately managed with oral anticholinergics.	Aug-24		
Red		Oxytocin (includes in combination)		1	All licensed indications	Oct-25		
Red		Ozanimod		1	In line with positive NICE TA recommendations	Nov-23		Ozanimod NICE information
Red		Paclitaxel		1,6	In line with positive NICE TA recommendations	Oct-25		Paclitaxel NICE information
Red		Palbociclib		1,6	In line with positive NICE TA recommendations	Oct-25		Palbociclib NICE information

Specialist only		Paliperidone depot injection **Traffic lighted specialist only in Barnsley, Rotherham & Sheffield only** (Traffic Lighted specialsit initiation & shared care in other Places)	Byannli® & Xeplion®		Schizophrenia	Oct-26		
Specialist only		Paliperidone MR tablets **Traffic lighted specialist only in Barnsley, Rotherham & Sheffield only** (Traffic Lighted specialsit initiation & shared care in other Places)			Schizophrenia	Oct-26		
Red		Palonosetron		1,6	All licensed indications	Oct-25		
Red		Panitumumab		1,6	In line with positive NICE TA recommendations	Dec-23		Panitumumab NICE information
Red		Panobinostat		1,6	In line with positive NICE TA recommendations	Oct-25		Panobinostat NICE information

Red		Paracetamol + ibuprofen solution for infusion		1	Use in adults for the short-term symptomatic treatment of acute moderate pain and the reduction of fever, where an intravenous route of administration is considered clinically necessary and/or when other routes of administration are not possible	Feb-24		
Red		Paraldehyde		1	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Red		Paricalcitol		1,6	All licensed indications	Oct-25		
Red		Pasireotide		1,6	All licensed indications	Oct-25		
Red		Patiromer		1	In line with positive NICE TA recommendations	Oct-25		Patiromer NICE information
Red		Pazopanib		1,6	In line with positive NICE TA recommendations	Oct-25		Pazopanib NICE information
Red		Pegaspargase		1,6	In line with positive NICE TA recommendations	Oct-25		Pegaspargase NICE information
Red		Pegfilgrastim (including biosimilars)		1	All licensed indications	Oct-25		
Red		Peginterferon (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25		Peginterferon NICE information
Red		Pegunigalsidase alfa		1,6	Fabry disease	Nov-23		NICE Pegunigalsidase+alfa information
Red		Pegvisomant		1,6	All licensed indications	Oct-25		
Red		Pegzilarginase		1,5	In line with positive NICE TA recommendations	Apr-26		Pegzilarginase NICE information

Red		Pembrolizumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Sep-23		Pembrolizumab NICE information
Red		Pemetrexed		1,6	In line with positive NICE TA recommendations	Oct-25		Pemetrexed NICE information
Red		Pemigatinib		1,6	In line with positive NICE TA recommendations	Oct-25		Pemigatinib NICE information
Red		Pentamidine		1	All licensed indications	Oct-25		
Red		Pentosan		1	In line with positive NICE TA recommendations	Oct-25		Pentosan NICE information
Red		Pentostatin		1	Hairy cell leukaemia	Oct-25		
Red		Pertuzumab (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25		Pertuzumab NICE information
Red		Phenylephrine + ketorolac		1	Use in adults for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery	Aug-24		
Red		Phenylephrine injection		1	For all indications. See red & grey lists	Oct-25		
Red		Pirfenidone		1,6	In line with positive NICE TA recommendations	Oct-25		Pirfenidone NICE information
Specialist only		Pirtobrutinib			In line with positive NICE TA recommendations	Sep-26		Pirtobrutinib NICE Information
Red		Pitolisant (dual classification)		1	Narcolepsy. See also Grey for other indications	Dec-25		Pitolisant NICE information

Red		Plasma-Lyte		1	Infusion - for use in adults, older patients and adolescents (age 12 years and over) for fluid replacement, as intraoperative fluid replacement, in haemorrhagic shock and clinical conditions requiring rapid blood transfusions, and in mild to moderate metabolic acidosis, also in case of lactate metabolism impairment.	Jul-26		Intravenous fluid therapy in adults in hospital
Red		Plerixafor		1,6	All licensed Indications	Oct-25		
Red		Polatuzumab (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25		Polatuzumab NICE information
Red		Pomalidomide		1,6	In line with positive NICE TA recommendations	Oct-25		Pomalidomide NICE information
Red		Ponatinib		1,6	In line with positive NICE TA recommendations	Oct-25		Ponatinib NICE information
Red		Ponesimod		1,6	In line with positive NICE TA recommendations	Oct-25		Ponesimod NICE information
Red		Posaconazole		1,6	All licensed indications	Oct-25		

Red		Potassium citrate modified-release tablet	Renodyra®	1	Use in adults for the treatment of patients with kidney stones and hypocitraturia, or chronic calcium oxalate stones; the treatment and prevention of recurrent uric acid lithiasis with or without calcium lithiasis and cystine lithiasis; the treatment of renal tubular acidosis with calcium nephrolithiasis	Apr-26		
Red		Pretomanid		1,6	TB in >14 year olds	Nov-24		NHS E document
Red		Procarbazine		1	All licensed indications	Oct-25		
Specialist only	Preferred -Hospital only	Progesterone Injection	Gestone®		Dysfunctional uterine bleeding. Maintenance of early pregnancy in women with a history of ≥3 consecutive unexplained miscarriages, and in selected cases as an adjunct to infertility treatment.	Sep-26		
Red		Progesterone micronised vaginal preparations (multiple traffic light classifications)		1	Supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles	May-26		Different products have different licensed indications - refer to the SPC.
Red		Protamine		1	Emergency treatment of poisoning (heparin reversal)	Oct-25		

Red		Quizartinib		1,6	For induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia	Nov-24		NICE TA1013
Red		Raltegravir		1,6	HIV	Oct-25		
Red		Ranibizumab (Branded/ biosimilar or in combination)		1,6	In line with positive NICE TA recommendations	Jun-23		Ranibizumab NICE information
Red		Rasburicase		1,6	Hyperuricaemia associated with cytotoxic drugs	Oct-25		
Red		Ravulizumab		1,6	In line with positive NICE TA recommendations	Feb-24		Ravulizumab NICE information
Red		Regorafenib		1,6	In line with positive NICE TA recommendations	Dec-23		
Red		Relugolix–estradiol–norethisterone (Dual traffic light status)	Ryeqo®	1,3	Treating symptoms of endometriosis	May-25		NICE TA1057
Red		Remdesivir (including in combination with other drugs)		1,3	Adults and children aged 12 years and older COVID-19 Treatment	Jun-23	Oct-25	Interim Clinical Commissioning Policy
Red		Reslizumab		1,6	In line with positive NICE TA recommendations	Oct-25		Reslizumab NICE information
Red		Ribavirin (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Ribavirin NICE information
Red		Ribociclib		1,6	In line with positive NICE TA recommendations	Sep-25		Ribociclib NICE Information
Red		Ribociclib (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Ribociclib NICE information
Red		Rilpivirine (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Rilpivirine NICE information

Red		Riociguat		1,6	All licensed indications	Nov-25		
Red		Ripretinib		1,6	In line with positive NICE TA recommendations	Jun-26		NICE TA 1146
Red		Risankizumab		1,6	In line with positive NICE TA recommendations	Oct-24		Risankizumab NICE Information
Red		Risdiplam		1,6	In line with positive NICE TA recommendations	Dec-23		Risdiplam NICE Information
Red		Ritlecitinib		1,6	Severe alopecia areata in people 12 years and over	May-24		
Red		Ritonavir (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Ritonavir NICE information
Red		Rituximab		1,6	In line with positive NICE TA recommendations	Dec-23		Rituximab NICE Information
Red		Romiplostim		1	In line with positive NICE TA recommendations	Nov-25		Romiplostim NICE information
Red		Romosozumab		1	In line with positive NICE TA recommendations	Nov-25		Romosozumab NICE information
Red		Ropeginterferon		1,6	All licensed indications	Nov-25		Ropeginterferon NICE TA in development
Red		Ropivacaine		1	All licensed indications	Nov-25		
Red		Roxadustat		1	In line with positive NICE TA recommendations	Nov-25		Roxadustat NICE information
Red		Rozanolixizumab		1,6	treating antibody-positive generalised myasthenia gravis	Jul-26		NICE TA 1155
Red		Rucaparib		1,6	In line with positive NICE TA recommendations	May-25		Rucaparib NICE Information
Red		Ruxolitinib		1,6	In line with positive NICE TA recommendations	Nov-23		NICE Ruxolitinib information
Red		Sacituzumab govitecan		1,6	In line with positive NICE TA recommendations	Sep-25		Sacituzumab+govitecan NICE TA
Red		Sapropterin		1,6	In line with positive NICE TA recommendations	Jul-24		Sapropterin NICE Information
Red		Sarilumab		1,6	In line with positive NICE TA recommendations	Nov-25		Sarilumab NICE information

Red		Sebelipase alfa (dual traffic light classification)		1,6	Wolman disease cross reference to Grey TLS	Feb-24		
Red		Secukinumab		1,6	In line with positive NICE TA recommendations	Feb-24		Secukinumab NICE information
Specialist only		Seladelpar			In line with positive NICE TA recommendations	Sep-26		Seladelpar NICE Information
Red		Selexipag		1,6	All licensed indications	Nov-25		
Red		Selinexor		1,6	In line with positive NICE TAs(including in combination with other drugs)			Selinexor NICE information
Red		Selpercatinib		1,6	In line with positive NICE TA recommendations	Sep-23		Selpercatinib NICE information
Red		Semaglutide injection (multiple Traffic Light entries for different indications)	Wegovy®	16	Reducing the risk of major adverse cardiovascular events in people with cardiovascular disease (NICE TA1152)and for managing overweight or obesity (NICE TA875) (Refer to Place Based Weight Management Pathways)	Sep-23		Semaglutide NICE information
Red		Serplulimab		1,6	Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	Jul-26		NICE TA1167
Red		Setmelanotide		1,6	For treating obesity and hyperphagia in Bardet-Biedl syndrome	Jul-24		
Red		Sevelamer		1	All licensed indications	Dec-25		

Red		Sildenafil (For Pulmonary Arterial Hypertension)	Revatio	1,6	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also sildenafil entries for Erectile Dysfunction.	May-25		NHS England Commissioning policy, also can be found on NHSE High Cost drugs list
Red		Siponimod		1,6		Nov-25		Siponimod NICE information
Red		Sodium Chloride oral solution		1,5	Oral sodium	Apr-26		
Red		Sodium Oxybate		1,6	Narcolepsy	Dec-23		
Red		Sodium Phenylbutyrate (Dual Classification)		1,6	All licensed indications, see also grey traffic light classification listing	Nov-25		
Red		Sofosbuvir (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Sofosbuvir NICE information
Red		Solriamfetol		1,6	In line with positive NICE TA recommendations	Dec-23		Solriamfetol NICE Information
Red		Somapacitan		1	Somapacitan for treating growth hormone deficiency in people 3 to 17 years	Jul-25		NICE TA 1066
Red		Sorafenib		1,6	In line with positive NICE TA recommendations	Dec-23		Sorafenib NICE Information
Red		Sotatercept		1,6	treating pulmonary arterial hypertension	Jul-26		NICE TA 1161
Red		Sotorasib		1,6	In line with positive NICE TA recommendations	Nov-25		Sotorasib NICE information
Red		Sotrovimab		1,3	Adults and young people aged 12 years and over Covid-19 Treatment	Jun-23		
Red		Sparsentan		1,6	In line with positive NICE TA recommendations	Sep-25		Sparsentan NICE Information
Red		Spesolimab		1,3,6	Spesolimab for treating generalised pustular psoriasis flares	Jul-25		NICE TA 1070

Red		Streptomycin		1	All licensed indications	Nov-25		
Red		Streptozocin		1	All licensed indications	Nov-25		
Red		Sucroferric oxyhydroxide		1,6	All licensed indications	Nov-25		
Red		Sugammadex		1	All licensed indications	Nov-25		
Red		Sunitinib		1,6	In line with positive NICE TA recommendations	Nov-25		Sunitinib NICE information
Red		Tadalafil (For Pulmonary Arterial Hypertension)	Adcirca	1,6	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also Tadalafil entries for Erectile Dysfunction.	May-25		NHS England Commissioning policy, also can be found on NHSE High Cost drugs list
Red		Tafamidis (dual traffic light combination)		1,6	In line with positive NICE TA recommendations	Jul-24		Tafamidis NICE Information Also see reference to Grey traffic light status
Red		Talazoparib		1,6	In line with positive NICE TA recommendations	Feb-24		Talazoparib NICE information
Red		Talimogene laherparepvec		1,6	In line with positive NICE TA recommendations	Nov-25		Talimogene NICE information
Red		Talquetamab		1,6	Relapsed and refractory multiple myeloma in line with positive NICE TA	Jan-26		Talquetamab NICE Information
Red		Tazobactan (including in combination with other drugs)		1	Antibiotic	Aug-24		
Red		Tebentafusp		1,6	In line with positive NICE TA recommendations	Feb-25		Tebentafusp NICE Information
Red		Teclistamab		1,6	Relapsed and refractory multiple myeloma	Jun-23		Teclistamab NICE Information
Red		Tedizolid		1	All licensed indications	Nov-25		
Red		Teduglutide		1,6	In line with positive NICE TA recommendations	Nov-25		Teduglutide NICE information

Specialist only	Preferred -Hospital only	Tegafur/ gimeracil/ oteracil			With cisplatin for advanced gastric cancer. As monotherapy or with oxaliplatin or irinotecan, with or without bevacizumab, for metastatic colorectal cancer where it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.	Sep-26		
Red		Temozolomide		1,6	In line with positive NICE TA recommendations	Jul-26		Temozolomide NICE Information
Red		Tenecteplase			Treating acute ischaemic stroke	Oct-24		NICE TA990
Red		Tenofovir (including in combinatin with other drugs)		1,6	HIV & also in line with positive NICE TA recommendations	Nov-25		Tenofovir NICE information
Specialist only		Teplizumab	Tzield		For delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes Pathway in development	Sep-26		NICE TA 1176
Red		Tepotinib		1,6	In line with positive NICE TA recommendations	Nov-25		Tepotinib NICE information
Red		Teriflunomide		1,6	In line with positive NICE TA recommendations	Nov-25		Teriflunomide NICE information
Red		Teriparatide		1	In line with positive NICE TA recommendations	Nov-25		Teriparatide NICE information
Red		Terlipressin		1	All licensed indications	Nov-25		
Red		Tetracosactide		1	All licensed indications	Nov-25		

Red		Tezacaftor (in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Tezacaftor NICE information
Red		Tezepelumab		1	In line with positive NICE TA recommendations	Nov-25		Tezepelumab NICE information
Red		Thalidomide		1,6	In line with positive NICE TA recommendations	Nov-25		Thalidomide NICE information
Red		Thiamine hydrochloride injection		1	Thiamine deficiency conditions	Jan-25		
Red		Thiotepa		1	All licensed indications	Nov-25		
Red		Tigecycline		1	All licensed indications	Nov-25		
Red		Tildrakizumab		1	In line with positive NICE TA recommendations	Nov-25		Tildrakizumab NICE information
Red		Tioguanine		1	All licensed indications	Nov-25		
Red		Tirofiban		1	In line with positive NICE TA recommendations	Nov-25		Tirofiban NICE information
Red		Tirzepatide weight management - patients who fulfill NICE TA 1026 AND meet NHS SY Specialist Weight Management Service referral criteria [Multiple traffic light classifications]		6	For managing overweight and obesity in patients who fulfil NICE TA1026, including those in **cohort one & two** who may not want or be suitable for management in primary care AND meet NHS SY SWMS referral criteria.	May-25		Tirzepatide weight management Information
Red		Tisagenlecleucel		1,6	In line with positive NICE TA recommendations	Feb-24		Tisagenlecleucel NICE information
Red		Tisotumab vedotin		1,6	treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment	Jul-26		NICE TA1164
Red		Tivozanib		1,6	In line with positive NICE TA recommendations	Nov-25		Tivozanib NICE information

Red		Tocilizumab		1,3	In line with positive NICE TAs. COVID-19 indication is for infusion only	Jun-23		Tocilizumab NICE Information
Red		Tofacitinib		1	In line with positive NICE TA recommendations	Nov-23		Tofacitinib NICE information
Red		Tolvaptan		1,6	In line with positive NICE TA recommendations	Nov-25		Tolvaptan NICE information
Red		Topotecan		1,6	In line with positive NICE TA recommendations	Feb-24		Topotecan NICE information
Red		Trabectedin		1,6	In line with positive NICE TA recommendations	Feb-24		Trabectedin NICE Information
Red		Tralokinumab		1,6	In line with positive NICE TA recommendations	Nov-25		Tralokinumab NICE information
Red		Trametinib		1	In line with positive NICE TA recommendations	Sep-23		Trametinib NICE information
Red		Trastuzumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Traztuzumab NICE information
Red		Treosulfan		1,6	In line with positive NICE TA recommendations	Feb-24		Treosulfan NICE information
Red		Treprostinil		1,6	All licensed indications	Nov-25		
Red		Tretinoin		1	All licensed indications	Nov-25		
Red		Trientine		1,6	All licensed indications	Nov-25		
Red		Trifluridine/Tipiracil		1,6	In line with positive NICE TAs	Feb-24		Trifluridine/Tipiracil NICE Information
Red		Ublituximab		1,6	In line with positive NICE TA recommendations	Jan-25		Ublituximab NICE Information
Red		Ulipristal acetate 5mg tablets	Esmya®	1	Fibroids	Feb-24		
Red		Upadacitinib		1,6	Crohn's disease	Jul-23		NICE TA905
Red		Upadacitinib		1,6	In line with positive NICE TA recommendations	Nov-25		Upadacitinib NICE information
Red		Ustekinumab		1,6	In line with positive NICE TA recommendations	Nov-25		Ustekinumab NICE information

Red		Vadadustat		1,6	In line with positive NICE TA recommendations	Aug-24		Vadadustat NICE Information
Red		Valganciclovir		1	All licensed indications	Nov-25		
Red		Vamorolone		1,6	In line with positive NICE TA recommendations	Feb-25		Vamorolone NICE Information
Red		Vancomycin injection		1,5		Apr-26		
Red		Vanzacaftor-tezacaftor-deutivacaftor		1,6	treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over	Sep-25		NICE TA 1085
Red		Varicella (chickenpox) vaccine	Varilrix®,Varivax®	6	Vaccine for use Prior to Immunosuppression, in Adults and Children without Immunity	Oct-23		
Red		Vasopressin		1	All licensed indications	Nov-25		
Red		Vedolizumab		1,6	In line with positive NICE TA recommendations	Feb-24		Vedolizumab NICE Information
Red		Velmanase alfa		1,6	Alpha-mannosidosis	Feb-24		
Red		Venetoclax (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Venetoclax NICE information
Red		Verteporfin		1	All licensed indications	Nov-25		
Red		Vinblastine		1	All licensed indications	Nov-25		
Red		Vincristine		1	All licensed indications	Dec-25		
Red		Vindesine		1	All licensed indications	Dec-25		
Red		Vinorelbine		1	All licensed indications	Dec-25		Volanesorsen NICE information
Red		Vismodegib		1,6	In line with positive NICE TA recommendations	Feb-24		Vismodegib NICE information
Red		Voclosporin		1,6	In line with positive NICE TA recommendations	Feb-24		Voclosporin NICE information
Red		Volanesorsen		1,6	In line with positive NICE TA recommendations	Dec-25		
Red		Vonicog alfa			von willebrand disease	Dec-25		Voretigene neparvovec NICE information

Red		Vorasidenib	Voranigo®	1,6	In line with positive NICE TA recommendations	Dec-25		NICE TA 1147
Red		Voretigene neparvovec		1,6	In line with positive NICE TA recommendations	Dec-25		
Red		Voriconazole		1,6	All licensed indications	Dec-25		
Red		Vutrisiran		1,6	In line with positive NICE TA recommendations	Sep-23		Vutrisiran NICE information
Red		Zanidatamab		1,6	In line with positive NICE TA recommendations	Jun-26		NICE TA 1153
Red		Zanubrutinib (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Dec-23		Zanubrutinib NICE information
Red		Zidovudine (in combination with other retroviral drugs)		1,6	HIV	Dec-25		
Red		Zolbetuximab (including in combination)		2	Advanced gastric or gastro-oesophageal junction adenocarcinoma	Apr-25		NICE TA 1046
Red		Zoledronic acid		1	All licensed indications	Dec-25		
Red		Zuclopenthixol Acetate		1	Short term management of acute psychosis	May-25		
Amber		ACARIZAX 12 SQ-HDM		1,3	House dust mite sensitisation Sublingual Immunotherapy (SCP). Current SCP covers children aged ≥12 years and adults. The SCP will be updated to include children aged 5-11 years in line with the updated NICE TA.	May-22	Feb-27	Sublingual Immunotherapy (SCP)
Amber		Acetazolamide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Amber		Alimemazine (dual traffic light classification)	Izenal SF or Alfresed (sugary version)	1,2,3	Treatment of sleep disorders in Children (from Specialist Clinicians at Sheffield Children's NHS Foundation Trust Tertiary Sleep Service only)	Aug-24	Aug-29	SY Alimemazine SCP
Amber		Amantadine (Multiple traffic light classification)		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Apomorphine		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Azathioprine (dual Traffic Light status)		1,2 ab	In line with Place based shared care protocols, preparations within the documents. . Cross reference to Grey traffic light status for high strengths (75mg &100mg) Doncaster has a Red traffic light status - see Place based formulary for further information	Apr-24		
Amber		Brivaracetam		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Bromocriptine		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Cabergoline		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Carbamazepine		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Amber		Cenobamate (see appendix information for community pharmacy re ordering)		1,2,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Shared Care		Ciclosporin (oral)			In line with place shared care protocols	Sep-26		Ciclosporin Shared Care Information
Shared care		Cinacalcet (dual categorisation)			Primary hyperparathyroidism in line with Place based shared care protocols where available. Also see Specialist only entry.	Oct-26		Cinacalcet shared care protcols
Amber		Clobazam		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Clonazepam		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Co-beneldopa		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Co-careldopa		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Shared care		Colistimethate sodium (colistin sulfomethate sodium) (dual categorisation)			Refer to shared care protocols where applicable for non-cystic fibrosis bronchiectasis indication. See specialist only category for cystic fibrosis.	Oct-26		Colistimethate sodium shared care protocols

Shared Care		Cyproterone Acetate **Traffic lighted shared care only in Rotherham** (Traffic Lighted specialist initation for all other Places)			prostate cancer	Oct-26		
Amber		Dalteparin		1,2,3	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP Refer to Place based guidance/ SCP for further information	Nov-24		Medicines Optimisation Information
Amber		Dapsone (dual classification)		1,2,3	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP	Nov-24		Medicines Optimisation Information
Amber		Denosumab 60mg Injection	Stoboclo	1,2,3	Indications as outlined in the Shared Care Protocol. Please note 120mg strength (XGEVA) is RED.	Aug-24	Aug-29	SY Denosumab SCP
Amber		Diazepam (rectal)		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Shared Care		Disulfiram **Traffic lighted shared care in Rotherham only** (Traffic Lighted specialist initation & specialist only in other Places)			Alcohol disorders	Oct-26		

Shared care		Enoxaparin			In line with place based shared care protocols where available	Oct-26		Enoxaparin shared care protocols
Amber		Entacapone		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Eslicarbazepine		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Ethosuximide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Finerenone (dual traffic light status)		7	Chronic Kidney Disease in Type 2 Diabetes See also all settings	Jun-24	Dec-25	SY Finerenone SCP
Amber		Gabapentin		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		GRAZAX 75,000 SQ-T oral lyophilisate		1,3	Grass pollen sensitisation	May-22	Feb-27	Sublingual Immunotherapy (SCP)
Amber		Hydrocortisone MR 5mg & 10mg capsules	Efmody®	1	Congenital adrenal hyperplasia	Sep-23		Link to SCP (when uploaded on website)
Amber		ITULAZAX 12 SQ-Bet sublingual lyophilizate		7	Moderate-to-severe allergic rhinitis and/or conjunctivitis allergen extract of pollen from white birch Please note that Itulazax® is not for use in children via shared care this is under review	Mar-26		Sublingual Immunotherapy (SCP)
Amber		Lacosamide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Lamotrigine		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Levetiracetam		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Liothyronine		1,2,3	From NHS Endocrinologists only	Aug-24	Aug-29	SY Liothyronine SCP

Amber		Melatonin (Dual traffic light classification)		1,3	As per place shared care protocols	Oct-23		Melatonin Information
Amber		Melatonin (Dual traffic light classification)		1,3	For the treatment of sleep disorders in children and young people up to 18 years (off-label use)	Dec-25	Dec-28	Refer to Place based formularies SY Children's and young peoples Melatonin SCP
Amber		Methylphenidate		1,2,3	Use as part of a comprehensive treatment programme for attention-deficit/ hyperactivity disorder in children aged ≥6 years and adults when remedial measures alone prove insufficient	Feb-24		Methylphenidate Information
Amber		Midazolam (Buccal)		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Modafinil		1,3	Refer to Place based Shared care protocol/ prescribing guidance	Nov-20	Nov-25	Modafinil Information
Amber		Mycophenolate (dual traffic light classification)		1,2,3	TLS Amber for shared care protocols and Red for all other indications Refer to SCP at Place	Aug-24		Mycophenolate Information
Amber		Opicapone		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Oxcarbazepine		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Shared Care		Paliperidone depot injection **Traffic lighted shared care in Doncaster with patients NOT on the SMI register only** (Traffic Lighted specialsit initiation & specialist only in other Places)	Byannli® & Xeplion®		Schizophrenia-Doncaster patients not on the SMI register	Oct-26		
Shared Care		Paliperidone MR tablets **Traffic lighted shared care in Doncaster with patients NOT on the SMI register only** (Traffic Lighted specialsit initiation & specialist only in other Places)			Schizophrenia Doncaster patients not on the SMI register	Oct-26		
Amber		Perampanel		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Phenobarbital		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Phenytoin		1,3		Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Pramipexole		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Pregabalin		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Amber		Primidone		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Rasagiline		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Relugolix–estradiol–norethisterone acetate (Dual traffic light status)	Ryeqo®	3	Uterine Fibroids	Oct-24	Oct-27	SY Relugolix-estradiol-norethisterone acetate (Ryeqo®) Shared Care Protocol
Amber		Riluzole		1,3	Riluzole Shared Care Protocol(see Place formulary)	Oct-23		Riluzole Medicines Optimisation Information
Amber		Ropinirole		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Rotigotine		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Rufinamide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Safinamide		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Selegiline		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Sodium Valproate		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Stalevo® (levodopa, carbidopa and entacapone)		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber		Stiripentol		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Topiramate		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Amber		Vigabatrin		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber		Zonisamide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber G		Alpha Tocopheryl Acetate (Vitamin E)		1,2b	Following British National Formulary (BNF)advice	Mar-26		Alpha-Tocopheryl BNF Information
Amber G		Alprostadil cream		1	Erectile dysfunction	Mar-26		
Amber G		Amantadine (multiple traffic light classification)			In Line with NICE guidance (Multiple-Sclerosis)	Feb-24		
Specialist Initiation		Apixaban (multiply categorisation)			Treatment and prevention of DVT and/or PE. See also specialist only & all settings	Oct-26		NICE TA341
Amber G		Atogepant (dual traffic light status)		1,2b	Prevention of episodic and chronic migraine. See also all settings entry for the treatment of acute migraine.	Feb-26		Atogepant Amber G Guideline
Specialist Initiation		Aviptadil / phentolamine	Invicorp®		Erectile dysfunction	Oct-26		
Specialist Initiation		Calcium acetate			Hyperphosphataemia	Oct-26		
Specialist Advice		Chlordiazepoxide **Traffic lighted specialist advice only in Rotherham** (Traffic Lighted Red for all other Places)			Alcohol withdrawal	Oct-26		
Specialist Initiation		Co-enzyme Q10			For an indication of 'Metabolic disorders ONLY'	Oct-26		Formularies – BIMDG

Specialist Advice		Cyproterone Acetate			Trans Women prescribing	Oct-26		Trans woman Guidance
Specialist Initiation		Cyproterone Acetate **Traffic lighted specialist initation in Barnsley, Doncaster & Sheffield** (Traffic Lighted shared care in Rotherham only)			prostate cancer	Oct-26		
Specialist Initiation		Dabigatran etexilate (dual categorisation)			Treatment and prevention of DVT and/or PE. See all settings category for other indication.	Oct-26		
Amber G		Dexcom One +			Continous Glucose Monitor	Nov-24		
Specialist Initiation		Disulfiram **Traffic lighted specialist initation in Barnsley & Sheffield only** (Traffic Lighted shared care & specialist only in other Places)			Alcohol disorders	Oct-26		
Amber G		Donepezil		1,2b	Mild to moderately severe dementia in Alzheimer's disease	Jun-26		SY Dementia Guidelines

Specialist Advice		Dulaglutide injection for type 2 diabetes **Traffic lighted specialist advice in Barnsley & Sheffield only** (Traffic Lighted all settings in other Places)	Trulicity®		Dulaglutide injection (Trulicity®) for type 2 diabetes. Prescribe by brand.	Oct-26		
Amber G		Duloxetine		1	Stress Urinary Incontinence	Sep-23		NICE NG123
Amber G		Eflornithine cream		1,2	Treatment of facial hirsutism in women	Jul-23		NICE guidance
Amber G		Fentanyl (Immediate release)		1,2b	For patients undergoing palliative care treatment as per NHSE guidance	Dec-23		NHS E Guideline
Amber G		Freestyle Libre 2+			Continous Glucose Monitor	Nov-24		SY CGM Guidance
Amber G		Freestyle Libre Flash Glucose Monitoring System		1,2		Sep-23		SY CGM Guidance
Amber G		Galantamine		1,2b	Mild to moderately severe dementia in Alzheimer's disease	Jun-26		SY Dementia Guidelines
Amber G		Hydrocortisone oral solution		1,2a	Dual classification	Jun-24		
Amber G		Ibandronic acid		1,2b	Adjuvant therapy in early breast cancer	Feb-24		Ibandronic acid SY Guidance
Specialist Advice		Icosapent ethyl			Lipid modifying drug	Oct-26		NICE TA805
Amber G		Latanoprost/netarsudil eye drops	Roclanda®		Previously treated primary open-angle glaucoma or ocular hypertension	Feb-26		NICE TA 1009

Specialist Advice		Liraglutide injection for type 2 diabetes **Traffic Lighted specialist advice only in Barnsley & Sheffield** (Traffic Lighted all settings in other Places)	Biosimilars (Victoza® brand discontinued)		Liraglutide injection for type 2 diabetes. Note: as there are various brands of liraglutide injection available with different licenses, where liraglutide injection is prescribed, this should be by brand.	Oct-26		
Amber G		Memantine (also see grey entry for memantine orodispersible tablet formulation)		1,2b	Moderate to severe dementia in Alzheimer's disease	Jun-26		SY Dementia Guidelines
Amber G		Metolazone 5mg	(Xaqua®)		Oedema related to kidney disease and Congestive Heart Failure (CHF)	Feb-24		Metolazone guideline
Specialist Initiation		Paliperidone depot injection **Traffic lighted specialist initation in Doncaster with patients on the SMI register only** (Traffic Lighted shared care & specialist only in other Places)	Byannli® & Xeplion®		Schizophrenia-Doncaster patients on the SMI register	Oct-26		

Specialist Initiation		Paliperidone MR tablets **Traffic lighted specialist initation in Doncaster with patients on the SMI register only** (Traffic Lighted shared care & specialist only in other Places)			Schizophrenia Doncaster patients on the SMI register only	Oct-26		
Amber G		Progesterone 400mg soft vaginal capsules	Prometrium®	1,2b	Indicated for the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages	Feb-26		
Amber G		Progesterone micronised vaginal preparations (multiple traffic light classifications)		1,2b	Prevention of preterm birth.	May-26		Different products have different licensed indications - refer to the SPC.
Amber G		Reboxetine		1,2a	Treatment of depression	Dec-23		
Specialist Initiation		Relugolix	Orgovyx®		Treating hormone-sensitive prostate cancer	Oct-26		Relugolix guidance
Amber G		Rimegepant (Dual classification)		1,2b	Prevention of episodic migraine Also cross reference to Green classification)	Feb-26		Rimegepant Amber G Guidance
Amber G		Rivastigmine		1,2b	Mild to moderately severe dementia in Alzheimer's disease	Jun-26		SY Dementia Guidelines

Specialist Advice		Semaglutide injection for type 2 diabetes **Traffic lighted specialist advice in Barnsley & Sheffield only** (Traffic Lighted all settings in other Places)	Ozempic®		Indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes.	Oct-26		
Specialist Advice		Semaglutide tablets for type 2 diabetes **Traffic lighted specialist advice in Barnsley & Sheffield only** (Traffic Lighted all settingsin other Places)	Rybelsus®		Semaglutide tablets (Reybelsus®) for type 2 diabetes. Note: as there are two brands of semaglutide tablets available with different licenses, where semaglutide tablets are prescribed, this should be by brand.	Oct-26		
Specialist Initiation		Sodium zirconium cyclosilicate (SZC)			Persistent hyperkalaemia in patients with chronic kidney disease(CKD) (stages 3b-5) or heart failure based on NICE TA1148	Oct-26		Sodium Zirconium cyclosilicate guidelines

Amber G		Tirzepatide type 2 diabetes		1,2b	Treating type 2 diabetes.	Dec-23		SY Tirzepatide Amber G Guidance
Green		Fluoride toothpastes (2800ppm and 5000ppm) ONLY (specialist recommendation)			High strength toothpaste (specialist recommendation) only when prescribing in line with the exceptions in the Position Statement.	May-25		SY Dental Statement
Green		5 Fluorouracil and salicylic acid 5FU-SA	Actikerall		Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green		Acetic acid 2%			Acute otitis externa	Mar-26		
Green		Aciclovir 3% eye ointment			Herpes Simplet infection	Aug-24		
Green		Adapalene plus benzoyl peroxide 0.1%/2.5%.			Acne	Mar-26		
Green		Adrenaline (Dual Traffic Light status)				Apr-24		
Green		Alginate antacid				Jun-24		
Green		Alverine with Simeticone			Irritable bowel syndrome	Jun-24		
Green		Aminophylline hydrate tablets			Indicated in adults and children aged 6 years and above for the treatment and prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease and chronic bronchitis. Indicated in adults for the treatment of left ventricular and congestive cardiac failure	Aug-24		

Green		Amlodipine			Hypertension Chronic stable angina pectoris Vasospastic (Prinzmetal's) angina.	Jul-26		
All settings	Preferred	Apixaban (multiply categorisation)			Anticoagulant for stroke and systemic embolism prevention in AF See also Specialist only category & Specialist initation	Sep-26		
Green		Aspirin			All licensed indications & off-licensed use for hypertension in pregnancy	Nov-25		Aspirin in pregnancy NICE information
All settings		Atogepant (dual traffic light status)	Aquipta		For the acute treatment of migraine in adults. Amber G status for prevention of episodic and chronic migraine.	Sep-26		SY Migraine Information
Green		Beclometasone /formoterol/glycopyrronium inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Beclometasone inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.

Green		Beclometasone/ Formoterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance docuements. Consider using the lowest cost product which meets the needs of the individual patient.
All settings	Preferred	Bempedoic acid and bempedoic acid-ezetimibe combination	Nilemdo and Nustendi		For treating primary hypercholesterolaemia or mixed dyslipidaemia	Sep-26		SY lipid guidance
Green		Betamethasone plasters			Corticosteriods (topical)	Aug-24		Betamethasone Plasters BNF information
Green		Bilastine			Antihistamine	Mar-26		Follow Place formularies / guidelines for further information
Green		Bimatoprost + timolol				Mar-25		
Green		Bismuth subcitrate potassium , metronidazole , tetracycline hydrochloride 14mg/125mg/125mg	Pylera ®		Helicobacter Pylori eradication	May-26		Green for first line or second line use only to treat H.Pylori in those with penicillin allergy. See link for clinical scenarios where consideration may be indicated. Note the licensed treatment is for 10 days.

All settings	Preferred :The first choice beta-blocker is dependent on indication, refer to local guidance where available. Use the lowest cost suitable formulation: standard tablets first, then orodispersible tablets, then oral solution.	Bisoprolol			Treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ACE inhibitors, and diuretics, and optionally cardiac glycosides	Sep-26		
Green		Brimonidine gel			Facial erythema of rosacea	Jun-24		
Green		Budesonide inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Budesonide/formoterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Buprenorphine			Pain	Feb-26		
Green		Bupropion			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek cks for supporting information	Oct-24		
Green		Canagliflozin			Type 2 diabetes in adults	Nov-24		

All Settings	Preferred. Carbimazole 5mg and 20mg tablets should be used where clinically appropriate in preference to the 10mg and 15mg tablets which have a significantly higher cost. Carbimazole 2.5mg/ml sugar-free oral solution has a higher cost in comparison to carbimazole tablets.	Carbimazole			Anti-thyroid agent	Oct-26		
Green		Cetirizine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		Follow Place formularies / guidelines for further information
Green		Chlorphenamine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		Follow Place formularies / guidelines for further information
Green		Cimetidine				Jun-24		
Green		Ciprofloxacin			Only as per NICE CKS antibiotics	Jun-24		
Green		Clindamycin/Tretinoin gel			Topical preparations for acne	Jun-24		
Green		Co-codamol 8/500mg for acute pain in adults			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
Green		Covid-19 vaccine			Covid -19 vaccine-as per NHS green book	May-23		

Green		Cyanocobalamin 50 microgram tablets (dual traffic light classification)	Cyanocominn®		As per NHSE guidance - only to be prescribed in those with medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery that results in malabsorption. Continuing need should however be reviewed on a regular basis. OTC advised if deficiency dietary related	May-23		
Green		Cytisinicline (cytisine)			To aid smoking cessation	May-26		**Commissioned services must be used as the standard pathway. Primary care prescribing is only permitted in exceptional circumstances where these services are inaccessible.** **Please see CKS for supporting information (Cytisinicline | Prescribing information | Smoking cessation | CKS | NICE)**
All Settings		Dabigatran etexilate (dual categorisation)			Anticoagulant for stroke and systemic embolism prevention in AF. See specialist initiation category for other indication	Oct-26		

Green		Dapagliflozin			Chronic heart failure with preserved or mildly reduced ejection fraction & Chronic kidney disease & Type 2 diabetes	Mar-26		SY Prescribing Guidelines For The Use Of SGLT2 Inhibitors In The Management Of Chronic Heart Failure
Green		Daridorexant			Insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months, in line with the SYICB insomnia management pathway and NICE TA.	Mar-26		SY Daridorexant information
Green		Dekas plus liquid (dual traffic light classification)			Children under 3 years with Cystic fibrosis Also see Grey Traffic Light Status	Oct-23		
Green		Desloratadine			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
Green		Desogestrel 75microgram,Drospirenone 4mg ,Levonorgestrel 30micrograms ,Norethisterone 350micrograms	Prescribe as generic		Progestogen-Only Contraceptives	Jun-26		SY Oral Contraception prescribing formulary
Green		Dexamethasone sodium phosphate eye drops				Jun-24		
Green		Diclofenac 3% gel	Solaraze®		Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green		Diltiazem 2% cream/ ointment			anal fissure	Jun-24		
Green		Dorzolamide eye drops				Jun-24		
Green		Dorzolamide/timolol eye drops				Jun-24		

All Settings		Doxycycline			Antibiotic	Oct-26		NICE antimicrobial guidance
Green		Doxylamine & Pyridoxine	Xonvea®		Nausea and vomiting during pregnancy	Apr-24		
Green		Drospirenone	Slynd®		Refer to Place based formularies	Dec-23		
All Settings		Dulaglutide injection for type 2 diabetes **Traffic lighted all settings in Doncaster & Rotherham only** (Traffic Lighted specialist advice in other Places)	Trulicity®		Dulaglutide injection (Trulicity®) for type 2 diabetes. Prescribe by brand.	Oct-26		
Green		Dutasteride				Jun-24		
Green		Dydrogesterone			For women with progesterone insufficiencies	Oct-25		
Green		Empagliflozin			Chronic heart failure & Chronic kidney disease & Type 2 diabetes	Mar-26		SY Prescribing Guidelines For The Use Of SGLT2 Inhibitors In The Management Of Chronic Heart Failure
Green		Enalapril				Jun-24		
Green		Ertugliflozin			Type 2 diabetes	Nov-24		
Green		Escitalopram			Treatment of major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorder (social phobia), generalised anxiety disorder and obsessive-compulsive disorder in adults	Aug-25		

Green		Esomeprazole				Jun-24		
Green		Estetrol + drospirenone				Jun-24		
Green		Estradiol and Progesterone				Jun-24		
Green		Estradiol plus Nomegestrol				Jun-24		
Green		Estradiol transdermal spray				Jun-24		
Green		Estradiol Valerate, dienogest	Qlaira		oral contraception	Aug-24		FSRH Clinical Guideline: Contraception for Women Aged over 40 Years
Green		Estriol pessray				Jun-24		
Green		Estriol 1 mg/g vaginal cream				Oct-24		
Green		Estriol gel				Jun-24		
Green		Ethinylestradiol / Desogestrel			Combined Oral Contraceptives **Refer to the SY oral contraception formulary for first line and second line product choices**	Jun-26		SY Oral Contraception prescribing formulary
Green		Ethinylestradiol / Drospirenone			Combined Oral Contraceptives **Refer to the SY oral contraception formulary for first line and second line product choices**	Jun-26		SY Oral Contraception prescribing formulary
Green		Ethinylestradiol / Gestodene			Combined Oral Contraceptives **Refer to the SY oral contraception formulary for first line and second line product choices**	Jun-26		SY Oral Contraception prescribing formulary

Green		Ethinylestradiol / Levonorgestrel			Combined Oral Contraceptives **Refer to the SY oral contraception formulary for first line and second line product choices**	Jun-26		SY Oral Contraception prescribing formulary
Green		Ethinylestradiol /Norgestimate			Combined Oral Contraceptives **Refer to the SY oral contraception formulary for first line and second line product choices**	Jun-26		SY Oral Contraception prescribing formulary
Green		Fesoterodine fumarate				Jun-24		
Green		Fexofenadine			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
All settings		Finerenone (dual traffic light status)			Chronic heart failure with preserved or mildly reduced ejection fraction See also Amber TLS	Sep-26		NICE TA1182
Green		Fludroxycortide			Refer to Place based formularies/guidelines for alternative listing	Jun-24		Medicines Optimisation Information
Green		Fluorouracil cream			Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green		Fluoxetine (with the exception of the 10mg tablet formulation - refer to the grey entry)			SSRI	Mar-26		
Green		Fluticasone /Salmeterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.

Green		Fluticasone furoate /umeclidinium /vilanterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Fluticasone furoate/vilanterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Fluvastatin 20mg & 40mg				Jun-24		
Green		Folic Acid				Jun-24		
Green		Formoterol /glycopyrronium /budesonide inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Gestodene/ethinylestradiol				Jun-24		
Green		Glyceryl Trinitrate ointment			anal fissure	Jun-24		
Green		Glycopyrronium /formoterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
All settings		Glycopyrronium bromide cream			For treating severe primary axillary hyperhidrosis	Sep-26		NICE TA1175
Green		Hepatitis A vaccine			Immunisation-as per NHS green book	Sep-23		

Green		Hepatitis B vaccine			Immunisation-as per NHS green book	Sep-23		
Green		Hydrocortisone (topical)				Jun-24		
Green		Hydrocortisone eye drops				Jun-24		
Green		Hydroxocobalamin (dual traffic light)			Pernicious anaemia and other macrocytic anaemias (prophylaxis & treatment)	Sep-25		
Green		Hydroxyzine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		Follow Place formularies / guidelines for further information
Green		Ibandronic acid 150mg			Osteoporosis	Jun-24		
Green		Ibuprofen			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
Green		Imiquimod cream			Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green		Indacaterol / glycopyrronium inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Influenza vaccine			Active immunisation for the prevention of influenza disease	Nov-25		
Green		Insulin needles<£5 per 100 needles			Refer to Place based formulary/ guidelines/other resources for further details	Sep-23		Medicines Optimisation Information

Green		Intravaginal device and pessaries			Non-surgical management of pelvic floor dysfunction	Feb-26		Prescribe on specialist recommendation and in line with NICE guidance
Green		Ipratropium Bromide			Refer to Place based Asthma/ COPD guidelines	Jun-24		Asthma and COPD Information
Green		Isosorbide mononitrate				Jun-24		
Green		Ivermectin 3mg tablets (dual traffic light status)			Treatment of scabies Traffic Lighted as Red for all other indications	Nov-24		
Green		Latanoprost + timolol eye drops			Refer to Place Glaucoma guidelines	Oct-24		Place Glucoma Guidelines
Green		Levocetirizine				Jun-24		
Green		Levofloxacin tablets			Antibiotic	Aug-24		Levofloxacin NICE information
Green		Levomepromazine			The 6.25mg tablet is more cost effective than the 6mg tablet.	Mar-24		
Green		Levonorgestrel				Jun-24		
Green		Levonorgestrel intrauterine delivery system				Jun-24		
Green		Linezolid **Traffic lighted Green only in Rotherham** (Traffic Lighted Red for all other Places)			Arrangements for the access to antimicrobials for Rotherham Community-based Patients with Infections in whom Linezolid are the only treatment options on advice from microbiology	Jul-26		Rotherham Place Information

All Settings		Liraglutide injection for type 2 diabetes **Traffic Lighted all settings only in Doncaster & Rotherham** (Traffic Lighted specialist advice in other Places)	Biosimilars (Victoza® brand discontinued)		Liraglutide injection for type 2 diabetes. Note: as there are various brands of liraglutide injection available with different licenses, where liraglutide injection is prescribed, this should be by brand.	Oct-26		
Green		Lodoxamide eye drops				Jun-24		
Green		Loratadine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		Follow Place formularies / guidelines for further information
Green		Macrogol 3350 sachet				Jun-24		
Green		Mebeverine				Jun-24		
All Settings	In line with NICE CKS Dysmenorrhoea and NICE CKS Menorrhagia, should be reserved for use after both ibuprofen and naproxen have been considered. Mefenamic acid has a relatively narrow margin of safety in overdose, with serious toxicity, particularly convulsions reported, which if prolonged or recurrent, require treatment BNF: Mefenamic Acid – side-effects	Mefenamic Acid 250mg capsules and 500mg tablets				Oct-26		Management of menorrhagia (heavy menstrual bleeding)

Green		Melatonin (2mg m/r) (Dual traffic light classification)			Insomnia in adults aged 55 years and over	Jun-26		Inline with the SY insomnia adult pathway
Green		Meloxicam			NSAID	Oct-25		Refer to Place based formularies
Green		Methenamine hippurate 1g tablets			Urinary tract infection	Apr-23		NICE NG112
Green		Mirabegron			In line with positive NICE TA recommendations			Mirabegron NICE Information
Green		Misoprostol (multiple traffic light classifications)			GI and musculoskeletal	Oct-25		
Green		Mometasone including combination products			Refer to Place based Asthma/ COPD guidelines	Jun-24		Asthma and COPD Information
Green		Morphine sulphate			Cross reference Traffic Light Status Red	Jun-24		
Green		Nabumetone				Jun-24		
Green		Nicotine replacement products eg Patches,gum,lozenges,inhalators, sprays and sublingual tablets			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek CKS for supporting information	Oct-24		
Green		Nifedipine				Jun-24		
Green		Ofloxacin			Only as per NICE CKS antibiotics	Jun-24		

Green		Olopatadine hydrochloride, Mometasone furoate monohydrate	Ryaltris		Indicated in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis	May-24		
Green		Ondansetron				Jan-26		
Green		Oral Combined hormone contraception				Aug-24		
Green		Ospemifene tablets			Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms	May-26		When prescribed in line with NICE NG23 1.5.11
Green		Phenazone 40mg/1g, Lidocaine 10mg/1g ear drops	Otigo®		Local symptomatic treatment and relief of pain in the middle ear	Apr-23		NICE NG91
Green		Pneumococcal polysaccharide conjugate vaccine			Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 years and older	Apr-26		Pneumococcal: the Green Book, Chapter 25
Green		Potassium Chloride Syrup 7.5% (equivalent to 1 mmol K+ per ml)			For the treatment of hypokalaemia and potassium deficiency of renal and extrarenal origin.	Jul-26		
Green		Prasterone pessaries			Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms	May-26		When prescribed in line with NICE NG23 1.5.10

Green		Pregabalin			Neuropathic pain	Apr-25		
Green		Primidone			Essential tremor	Feb-26		
Green		Promethazine			Antihistamine	Mar-26		Follow Place formularies / guidelines for further information
Green		Rehydration solutions/sachets (dual traffic light status)			For all other conditions than acute diarrhoea	Feb-24		
Green		Respiratory syncytial virus vaccine				Dec-23		RSV Green Book Chapter updated February 2025
Green		Rimegepant (Dual classification)			Treatment of acute migraine (cross reference to Amber G classification)	Jul-24		Neurology:migraine management guidelines
Green		Salbutamol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Salmeterol including combination products			SY Asthma/ COPD guidelines	Jun-24		Asthma & COPD guidelines and Information

All Settings		Semaglutide injection for type 2 diabetes **Traffic lighted all settings in Doncaster & Rotherham only** (Traffic Lighted specialist advice in other Places)	Ozempic®		Indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes.	Oct-26		
All Settings		Semaglutide tablets for type 2 diabetes **Traffic lighted all settings in Doncaster & Rotherham only** (Traffic Lighted specialist advice in other Places)	Rybelsus®		Semaglutide tablets (Reybelsus®) for type 2 diabetes. Note: as there are two brands of semaglutide tablets available with different licenses, where semaglutide tablets are prescribed, this should be by brand.	Oct-26		
Green		Sildenafil (generic) (For Erectile Dysfunction) 25mg,50mg,100mg (multiple traffic light classifications)			Erectile Dysfunction. See also entries in grey and red sections. Follow Place formularies / guidelines for further information	Apr-25		Erectile Dysfunction Information
Green		Sildenafil citrate			Erectile dysfunction	Sep-25		
Green		Spironolactone				Feb-25		

Green		Tadalafil 5mg (daily)			Refer to place based formularies for further details	Jul-25		Medicines Optimisation Information
Green		Tadalafil 10mg & 20mg (generic) (For Erectile Dysfunction) (multiple traffic light classifications)			Erectile Dysfunction. See also entries in grey and red sections. Follow Place formularies / guidelines for further information	Apr-25		Erectile Dysfunction Information
Green		Tiotropium /oldaterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Tirbaniulin ointment	Klisyri®		Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green		Tirzepatide (**cohort One & Two** weight management patients only) [Multiple traffic light classifications]			Traffic Lighted as Green for **cohort One & Two** weight management patients only (refer to local clinical guidance for further information).	Nov-25		Tirzepatide weight management Information
All Settings	Preferred. Use the anticholinergic medicine with the lowest acquisition cost which meets the patient's needs, refer to local guidance where available. Tolterodine 2mg/5ml oral suspension has a higher cost in comparison to tolterodine tablets.	Tolterodine			Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.	Oct-26		

Green		Tozinameran + famtozinameran	Comirnaty® Original/Omicron BA.4/5		Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged ≥12 years who have previously received at least a primary vaccination course against COVID-19	Jun-23		
Green		Umeclidinium/vilanterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green		Vardenafil			Erectile Dysfunction. Follow Place formularies / guidelines for further information	Nov-25		Erectile Dysfunction Information
Green		Varenicline			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek CKS for supporting information	Oct-24		Medicines Optimisation Information
Green		Vibegron			Treating symptoms of overactive bladder syndrome	Oct-24		NICE TA999

Green		Zolpidem			Short-term treatment of insomnia in adults in situations where the insomnia is debilitating or is causing severe distress for the patient	Sep-25		